



---

# Report on the Proposal to Reclassify Benzylpiperazine (BZP)

---

by

A/Professor Michael Dawson &  
Dr Alex Wodak

on behalf of accessUTS

for Chen Palmer Barrister & Solicitors, Wellington

21 March 2007

Project No: E07/61/003

accessUTS Pty Limited  
PO Box 123  
Broadway NSW 2007 Australia  
Tel +61 2 9514 1916 Fax +61 2 9514 1433  
ABN 55 098 424 312

accessUTS is a controlled entity of the University of Technology, Sydney

## TABLE OF CONTENTS

1. SUMMARY .....	3
2. CRITICISMS OF THE MRINZ STUDY.....	3
3. FINAL CONCLUSIONS .....	6
APPENDIX A – CURRICULUM VITAE OF A/PROF DAWSON .....	7
APPENDIX B – CURRICULUM VITAE OF DR WODAK.....	16

## 1. SUMMARY

The authors of this report (Dr Alex Wodak and Associate Professor Michael Dawson) have read the documents listed in the letter of instruction dated 2<sup>nd</sup> March 2007 as well as a number of other documents provided to us since that time.

In summary, it is our opinion that:

- The design of the benzylpiperazine (BZP)/3-trifluoromethylphenylpiperazine (TFMPP) study by MRINZ dated November 24<sup>th</sup> 2006 is fundamentally flawed to the extent that it is incapable of establishing that benzylpiperazine poses a moderate risk of harm, and thus the study should not be relied on by the EACD and/or the Minister as the basis for making any scheduling changes.
- The submission by STANZ dated 23<sup>rd</sup> March 2007 presents a strong case against the scheduling changes proposed by the Minister.
- The rate of side effects in “seasoned party drug users” reported in the BZP/TFMPP study by MRINZ dated November 24<sup>th</sup> 2006 is so high as to be difficult to accept.

## 2. CRITICISMS OF THE MRINZ STUDY

Our specific criticisms of the BZP/TFMPP study by MRINZ dated November 24<sup>th</sup> 2006 are summarised below:

1. Three drugs were administered at the same time thus making it impossible to attribute the observed side effects to BZP, alcohol, TFMMP or any combinations of the three drugs (or other constituent and/or contaminant contained in the commercial products used in the study) as inadequate data were provided to allow an estimation to be made of the separate effects of BZP, alcohol and TFMMP.
2. The study was carried out during the day in what can essentially be regarded a "clinical environment" which is not reflective of the usual environment in which such so called “party drugs” are taken.
3. Following on from the above point, there was no discussion of the concept of "drug, set and setting" as outlined by one of the leading researchers in the field Norman E. Zinberg, M.D in his book *Drug, Set, and Setting* (1984) by Yale University, Published by Yale University Press ISBN 0-300-03110-6. Zinberg argued that the ‘drug’ effects (e.g. type, dose, route of administration) were influenced by the (mental) ‘set’ (i.e. anxiety, depression, elation) and the (physical) setting (i.e. whether or not the environment was pleasing and sympathetic). The clinical environment is more likely to exacerbate negative affects and diminish pleasurable effects. Similar effects have been shown in laboratory animals (see Alexander, B. K., Beyerstein, B. L., Hadaway, P. F., & Coombs, R. B. (1981). Effects of early and later colony housing on oral ingestion of morphine in rats.

*Psychopharmacology Biochemistry and Behavior*, 58, 175-179). Rats in the idyllic surroundings of ‘Rat Park’ consumed less morphine than rats in less salubrious surroundings.

4. The insertion of a venous cannula into each subject given the minimal number of blood samples (taken from each subject) may have caused unnecessary anxiety and distress. The venous cannula appears to have been an unnecessary intrusion and may have exacerbated the effects of the clinical environment.
5. Given it is likely that most people would eat before going out and partying at night, there is no rationale for administration of the “party drugs” to each subject in the fasting state. Similarly there was no good reason for the subjects to remain fasting for a further four hours.
6. It appears that the formulations used in the study were prepared from commercially available “party drug” products. This is problematic for a number of reasons:

Firstly a properly conducted trial relating to the application for marketing approval of any drug substance (such as BZP) would normally use the encapsulated pure drug substance. If excipients were required, it would be necessary for the Company wishing to apply for marketing approval of the drug substance to provide a suitable justification for each excipient.

However it appears that the BZP/TFMPP study by MRINZ dated November 24<sup>th</sup> 2006 simply took commercially available products, analysed them for the content of BZP and TFMPP and used that material for the study (see below which is a quote from pages 7 and 8 of that report).

“The BZP/TFMPP study capsules were derived from the contents of two Jet and two Bliss capsules, repacked by equal weight into four two-tone green gelatine capsules. Each study capsule contained 75.0mg BZP.2HCl and 18.4mg TFMPP.2HCl. The placebo capsules comprised a homogenous mixture of lactose powder and thiamine packed into two-tone green gelatine capsules. Approximately 114mg of thiamine was added to each placebo capsule in order to assist blinding by replicating the characteristic smell of the Vitamin B complex contained in the Jet and Bliss party pills. As per industry recommended guidelines for party pill consumption, two capsules were given to each subject at time zero and two further capsules two hours later (time 2h or 120min). The total intervention dose given was thus equivalent to 300mg BZP.2HCl and 74mg TFMPP.2HCl.”

Secondly, the above is not only bad practice, but it also confounds the study because it leaves open the possibility that adverse effects noted in the study may have resulted from the other components of the capsule which were not assayed either qualitatively or quantitatively (see below which is a quote from page 15 of that report).

“The doses of various amino acids, antioxidants, minerals and vitamins contained in the capsules were not formally analysed for this study. The dose variability between capsules was greater in the commercially available preparation than those prepared by the hospital pharmacist for the study.”

Thirdly, it is also possible that the high rate of side effects was due to extraneous contamination in the re-packaged Jet® and Bliss® capsules. This is possible given that it appears the quality control of the manufacturing process of the many of the “party drug” products on the market does not appear to be satisfactory and there is no data supporting the proposition that the Jet® and Bliss® capsules were manufactured to a satisfactory degree of quality.

That such problems occur is a matter of fact, and exemplified by a recent case in Australia. In January 2003 the Therapeutic Goods Administration (TGA) of Australia recalled the travel sickness product Travacalm®, manufactured by Pan Pharmaceuticals. Travacalm® was reported to have resulted in almost 100 people being seriously affected, including 19 who required hospitalisation. Many of these victims reported very disturbing symptoms including, agitation, dizziness, confusion, delirium, hallucinations, and an inability to speak or walk.

Similarly it is known that contaminants in products may lead to severe adverse effects. In early 2000 one of the authors of this report (Associate Professor Michael Dawson) was asked to provide expert comment on a case where stock feed had become contaminated with monensin where the plaintiff claimed negligence on behalf of the respondent. That case was heard in a civil court in Australia and part of the report relating to that case is presented in the boxed text below.

Monensin and a number of other antimicrobial compounds are routinely incorporated into ruminant diets to improve production efficiency. One of the most widely used antimicrobial compounds in beef cattle diets is monensin.

Although suitable for cattle, monensin is highly toxic to other species such as horses and camels.

The respondent argued that problems “never happened” because they had “systems in place to ensure that no problems occurred.

Associate Professor Michael Dawson used two examples to show that problems do indeed happen, regardless of systems in place.

Example 1. On 30 September 1999, there was a major nuclear accident at the Tokaimura Fuel Conversion Plant in Japan. That accident occurred in spite of an “excellent quality system” being in place. Subsequent investigations revealed that a major cause of the accident was that the plant operators failed to follow the prescribed standard operating procedures.

Example 2. The Therapeutic Good Administration, a part of the Australian Government Department of Health and Aged Care has a system in place called the Uniform Recall Procedure for Therapeutic Goods. This system is in place because the Therapeutic Good Administration acknowledges that no matter how careful manufacturers of therapeutic goods are, there is always the possibility that the quality system may break down and that faulty or dangerous products may be released onto the market.

The pharmaceutical manufacturing industry in Australia is subject to much more stringent regulation than are other Australian industries such as the animal food industry. It is obvious that if release of faulty or contaminated products can occur in a well regulated industry like the pharmaceutical industry (for example during August 2000, the Therapeutic Good Administration ordered the recall of three medicines) that the frequency of such events will be greater in less controlled industries.

### 3. FINAL CONCLUSIONS

It is our opinion that the results from the study BZP/TFMPP study by MRINZ dated November 24<sup>th</sup> 2006 do not satisfy the criteria required for the outcomes of the study to be classified as “Level A evidence” as claimed on page 28 of the report.

We believe that design of the BZP/TFMPP study by MRINZ dated November 24<sup>th</sup> 2006 is fundamentally flawed to the extent that it is incapable of establishing that BZP poses a moderate risk of harm, and should not be relied on by the EACD and/or the Minister as the basis for making any scheduling changes.



**Associate Professor Michael Dawson**  
 Head of Department  
 Chemistry, Materials and Forensic Science  
 University of Technology, Sydney  
**accessUTS Consultant**



**Dr Alex Wodak**  
 Director, Alcohol and Drug Service  
 St. Vincent's Hospital  
**accessUTS Consultant**

## **APPENDIX A – CURRICULUM VITAE OF A/PROF DAWSON**

## Curriculum Vitae

## DR MICHAEL DAWSON

### Present Position:

Head, Department of Chemistry, Materials and Forensic Science, Faculty of Science, University of Technology, Sydney

### Qualifications:

- Doctor of Philosophy, 1983, University of Sydney
- Bachelor of Pharmacy (Honours), 1978, University of Sydney
- Listed on NSW Pharmacy Board Register, 1977

### Research Interests

- Synthetic route and impurity profiling of illicitly manufactured drugs
- Profiling of drug packaging materials
- Development of methods for the analysis of drugs in biological fluids and other complex matrices
- Functions and effectiveness of regulatory authorities
- Social impacts of the enforcement of non-complainant offences
- Reduction of harms associated with illicit drug use

### Subjects Currently Taught at UTS

- The Chemistry and Pharmacology of Illicit Drugs – 65741 – 6 credit points (lectures, practical classes and subject co-ordination)
- Analytical Chemistry 2 – 65409 – 6 credit points (lectures, practical classes and subject co-ordination)
- Forensic Research Project – 65856 – 24 credit points (honours student supervision)
- Forensic Toxicology 1 – 65542 – 6 credit points (lectures and practical classes)
- Forensic Toxicology 2 – 65642 – 6 credit points (practical classes)
- Environmental Chemistry – 65621 – 6 credit points (practical classes)
- Principles of Forensic Science - 65241 – 6 credit points (lectures)
- Complex Case Studies (Chemistry) - 65743 – 6 credit points (lectures)

Prior to 1999, I co-ordinated, lectured and demonstrated Environmental Chemistry – 65241 and Analytical Chemistry 1 – 65401.



## Membership of Professional Committees

- Member of the Pharmaceutical Subcommittee of the Australian Drug Evaluation Committee 1995 - 2003
- Member of the NSW Police Service Standing Committee on Amphetamine Control, 1993-1997
- Member, Australian Drug Law Reform Foundation 1993 - present
- Member of the executive of the Australian and New Zealand Forensic Science Society, 1995 - present
- Chairperson of the Analytical Chemistry Group, NSW Branch of the Royal Australian Chemical Institute, 1995 - 1997

## Membership of Societies and Professional Organisations

- Registered as a Pharmacist in the State of New South Wales, 1977 - present
- Member of the Pharmaceutical Society of Australia, 1977 - present
- Member of the Royal Australian Chemical Institute, 1983 - present
- Member of the Panel of Assessors, National Association of Testing Authorities, 1988 - present
- Member of the Australian Academy of Forensic Scientists 2000-present

## Membership of University Committees

- Member of the Dean's Advisory Committee – Faculty of Science, 2000 - present
- Member of the Courses Committee – Faculty of Science, 2000 - present
- Member of the Faculty Board, Faculty of Science UTS 1991-1992 and 2000-present
- Member of the Academic Board (from November 2001)
- Member of the Course Advisory Committee for the Bachelor of Science (Honours) in Applied Chemistry – Forensic Science, 1992 - present
- Member of the Course Advisory Committee for the Bachelor of Applied Science (Chemistry), 1992 – 1997
- Member of the Executive of the UTS Branch of the National Tertiary Education Committee - 1995 - 2001

## Membership of Charities

Board Member and Honorary Treasurer of the Damien Trimmingham Foundation – Family Drug Support

## PhD supervision

<u>Name</u>	<u>Project Description</u>
Tamsin Kelly	The use of LC/MS/MS in the analysis of morphine and its metabolites
Rebecca Webb	The role of morphine glucuronides in heroin overdose
Steven Armitage	Forensic investigation of illicitly manufactured ring and chain substituted amphetamines

Roy Day                      Some investigations of separation mechanism and applications of  
high performance liquid chromatography

Juuso Huttunen            Physical evidence in drug intelligence

### Honours Supervision

<u>Year</u>	<u>Name</u>	<u>Project Title</u>	<u>Grade</u>
2002	Carol Leung	Heroin purity by portable FTIR	Pending
2002	Edwina Hine	A new metabolite of nandrolone	Pending
2002	Lincoln Streatfield	Use of ionscan technology in clandestine laboratories	Pending
2001	Priscilla Barsenbach	Clandestine synthesis of methcathinone	1
2001	Alison Beavis	Differential metabolism of R and S ketamine	1
2001	Nicole Cretan	Validation of an HPLC method for substituted phenylethylamines	2/1
2001	Jenny Drew	ELISA as a substitute for RIA for the analysis of opioids	2/1
2001	Louise Keeble	Persistence of cocaine HCl in polymer bank notes	2/1
2000	Chris Austin	Pyrolysis G C/MS of drug packaging tapes	1
2000	Kim Wong	Analysis of antihypertensive drugs in post-mortem tissue samples Using LC-MS	2/1
2000	Quoc Hoang	Analysis of free and bound tetrahydrocannabinol in post-mortem Blood samples	2/1
1999	Tim Wellsmore	Enhancement of latent fingerprints on cartridge cases	1
1999	Ian Towney	Birch and HI/P reductions in clandestine laboratories	1
1999	Brett Fletcher	Development of an HPLC screening method for illicit recreational Drugs	1
1999	Amanda Bracey	Synthesis and forensic analysis of "Flatliner" (4 Methylthioamphetamine)	1
1998	Belina Tosi	Analysis of street level heroin samples	1

1998	Katie Williamson	Hydiodic red phosphorous reduction of N, N-dimethyl-3-phenyl-3-hydroxyproylamine	2/1
1997	Helen Salorous	Oripavine in Tasmanium opium	1
1997	Catherine Morrice	The determination of betahydroxybutyrate in urine	2/1
1997	Tiffany Bissett	Development of a gas chromatography method for cyanide in blood	2/1
1997	Karen Oswick	The separation of cannabinoids using counter current Chromatography	2/1

### Grant Applications

Applicant(s)	Title	Amount	Year	Agency
Dawson	Sugars by HPLC	\$29,525 <b>pending</b>	2002	ATN
Dawson et al	Speciation by ICP-MS	\$18,100 <b>pending</b>	2002	ATN
Dawson et al	Drug intelligence	\$281,148 <b>pending</b>	2002-2004	ARC-LINKAGE
Dawson et al	Amines on silica	\$28,843	2001	UTS-ILINK
Dawson et al	Drug intelligence	\$25,000	2001	UTS Incentive
DuPasquier & Dawson	Petrol profiling	\$25,000	2001	UTS Internal
Roux, Dawson et al	Microspectroscopy facilities	\$255,000	2000	ARC RIEF
Conn, Dawson et al	HPLC MS System	\$250,000	2000	ARC RIEF
Wilson, Dawson et al	Integrated GC/MS system	\$360,000	1999	ARC RIEF
Dawson et al	Forensic Investigations	\$60,000	1999	AFP

## Articles, Conference Presentations, Reports and other Public Output

### (i) Refereed Journal Articles

- **M Dawson**, Fryirs, B. F., Kelly, T., Keegan, J and Mather, L.E. A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma. *J. Chrom. Sci.* 40(1), 40-44 (2002)
- L Maher, W Swift and **M Dawson**. Heroin purity and composition in Sydney Australia. *Drug and Alcohol Review* 20, 439-448 (2001)
- Maynard P., Allwell K., Roux C., **Dawson, M.**, Royds D., A Protocol for the Forensic Analysis of Condom and Personal Lubricants Found in Sexual Assault Cases, *Forensic Science International*, 124, 2001,140-156.
- Lee, G. S., Brinch, K. M., Kannangara, K. **Dawson, M.** and Wilson, M.A. A methodology based on NMR spectroscopy for the forensic analysis of condoms . *J. Forensic Sci.* 2001, 46(4), 808-821.
- Lee, G. S., Taylor, R., **Dawson, M.** and Wilson, M.A. High-resolution solid state <sup>13</sup>C nuclear magnetic resonance spectra of 3,4-methylenedioxyamphetamine hydrochloride and related compounds and their mixtures with lactose. *Solid State Nuclear Magnetic Resonance.* 16, 225-237 (2000).
- Lee, G. S., Craig, D., Kannangara, K., **Dawson, M.**, Conn, C., Roberston, J. and Wilson, M.A. Analysis of methylenedioxy-N-methylamphetamine (MDMA) in "ecstasy" tablets by <sup>13</sup>C solid state nuclear magnetic resonance spectroscopy (NMR). *J. Forensic Sci.* 44(4) 761-771, (1999).
- Fryirs, B., **Dawson, M.** and Mather, L. A highly sensitive gas chromatographic-mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. *J Chromatogr. B*, 693(1), 51 - 57 (1997).
- Fryirs, B., Woodhouse, A., Huang, J., **Dawson, M.** and Mather, L. Determination of sub-nanogram concentrations of fentanyl in plasma by gas chromatography-mass spectrometry: Comparison with standard radio-immunoassay. *J Chromatogr. B*, 688, 79 - 85 (1997).
- Conn, C., **Dawson, M.**, Baker, A. T, Fryirs, B., and Keegan, J. The identification of N-acetylmethamphetamine in samples from a clandestine laboratory. *J Forensic Sci.* 41, (4), 645 - 647 (1996).
- **Dawson, M.** and McGee, C. M. Comparison between ethanol and methanol as the organic component in a reversed-phase high-performance liquid chromatographic analysis of leukotriene B4 and its metabolites in cell supernatants. *J. Chromatogr.* 532(2): 379-386 (1990).
- **Dawson, M.**, McGee, C. M., Smith, M. D. and Brooks, P. M. Methanol is a potent inhibitor of the metabolism of endogenous arachidonic acid. *Prostaglandins*, 39, No 4, 395-406 (1990).
- **Dawson, M.**, Smith, M. D. and McGee, C. M. Gas chromatography/negative ion chemical ionisation/tandem mass spectrometric quantification of indomethacin in plasma and synovial fluid. *Biomed. Environ. Mass Spectrom.*, 19(8): 453-458 (1990).
- Lacey, E., **Dawson, M.**, Long, M.A. and Than, C. A general method for tritium labelling of benzimidazole carbamates by catalytic exchange in dioxane solutions. *J. Labelled Compd. Radiopharm.*, XXVII(12), 1415-1427 (1989).
- **Dawson, M.**, McGee, C. M. Smith, M.D. and Vine, J. H. The synthesis of exchange deuterium labelled non-steroidal anti-inflammatory drugs using aluminium chloride and deuterium oxide. *J. Labelled Compd. Radiopharm.*, XXVII, No 6, 707-712 (1989).
- **Dawson, M.**, Vine, J. H, McGee, C. M., Nash, P. M. and Brooks, P. M. The disposition of biphenylacetic acid following topical administration. *Eur. J. Clin. Pharmacol.*, 33, 639-642 (1988).
- **Dawson, M.**, McGee, C. M., Brooks, P. M., Vine, J.H. and Watson, T. R. Quantification of leukotriene

- B4 in plasma and synovial fluid by gas chromatography mass tandem mass spectrometry. *Biomed. Environ. Mass Spectrom.*, 17: 205-211 (1988)
- **Dawson, M.**, McGee, C. M., Brooks, P. M., Vine, J.H., Lacey, E. and Watson, T. R. The quantitation of biphenylacetic acid in plasma and synovial fluid by gas chromatography mass spectrometry/mass spectrometry. *J. Chromatogr.*, 420(1), 29-134 (1987).
  - **Dawson, M.**, Vine, J.H., Forrest, M. J., McGee, C. M., Brooks, P. M. and Watson, T. R. The synthesis of deuterated leukotriene B4. *J. Labelled Compd. Radiopharm.*, XXIV(3), 291-295 (1987).
  - Rosario, C. C., Duke, J. H., Gill, **Dawson, M.**, Holder, G. M., Ghazy, T. and Long, M. A. The preparation of regiospecific tritiated and deuterated dibenzacridines by catalytic exchange. *J. Labelled Compd. Radiopharm.*, XXIV(1), 23-29 (1987).
  - **Dawson, M.**, Williams, P., Long, M. and Watson, T. R. The synthesis and purification of [4'-<sup>3</sup>H]-mebendazole. *J. Labelled Compd. Radiopharm.*, XXII, No. 7, 701-704 (1985).
  - **Dawson, M.**, and Watson, T. R. The effect of dose form on the bioavailability of mebendazole in man. *Br. J. Clin. Pharmacol.*, 19, 87-90 (1985).
  - **Dawson, M.**, Allan, R. J. and Watson, T. R. The pharmacokinetics and bioavailability of a tracer dose of [<sup>3</sup>H]-mebendazole in man. *Br. J. Clin. Pharmacol.*, 19, 79-86 (1985).
  - Allan, R. J., **Dawson, M.**, Roberts M. S., Watson, T. R. and Braithwaite, P. A. Cyst and host tissue concentrations of mebendazole in patients undergoing surgery for hydatid disease., *Med. J. Aust.*, 2, 383-384 (1983).
  - **Dawson, M.**, and Watson, T. R. 4-Amino-3-(3'-methoxy-carbonyl-2'-thioureido)benzophenone, a prodrug of mebendazole. *Eur. J. Drug Metab. Pharmacokin.*, 8(4), 329-334 (1983).
  - **Dawson, M.**, Allan, R. J. and Watson, T. R. The pharmacokinetics and bioavailability of mebendazole in Man: A pilot study using [<sup>3</sup>H]-Mebendazole. *Br. J. Clin. Pharmacol.*, 14, 453-455 (1982).

#### (ii) Lightly refereed journal articles

- **Dawson, M.** Heroin trails and tribulations. *Australasian Science*. Vol 20, No 5: 19-21 (1999).
- Roux, C., Maynard, P. and **Dawson, M.** FTIR spectroscopy applications in forensic science. *Chemistry in Australia*. 66(2), 11 - 15 (1999).
- Factors affecting stability of pharmaceutical products. **Dawson, M.** *The Australian Prescriber*. 17:2: 22 - 24 (1994).

#### (iii) Conference presentations

- **Dawson M.**, (2001). Who is making a killing out of drug related crime. *Fourth Australasian Freelance Journalists, Artists and Photographers Convention*, Sydney Australia, April 27-29
- **Dawson M.**, (2000). The T Room, *13<sup>th</sup> International Conference on Drug Policy Reform*, Washington DC, May 2000.
- Huttunen J., **Dawson M.**, Roux C., Maynard P., Gates K., Goulding J., Lennard C., Robertson J., (2000). Chemical and Physical Analysis of Packaging Tapes, *Scientific Working Group for Materials Meeting*, FBI Academy – Quantico, April 2000.
- **Dawson M.**, Fletcher B., Day R., Donkin P., (2000). Development of an Isocratic HPLC system for the Quantitation of illicit drugs, *Proceedings 15th International Symposium of the ANZFSS*, Gold Coast, March.
- **Dawson M.** (2000). Are University Physical Sciences Courses “Dead in the Water”, *Proceedings 15th*

- International Symposium of the ANZFSS, Gold Coast, March.*
- Kannangara K., Rowney I., Maynard P and **Dawson M.**, (2000). Lithium-Ammonia and Hydriodic Acid/Red Phosphorous Reductions in Clandestine Laboratories, *Proceedings 15th International Symposium of the ANZFSS, Gold Coast, March.*
  - Huttunen J., **Dawson M.**, Roux C., Maynard P., Gates K., Goulding J., Lennard C., Robertson J., (2000). Chemical and Physical Analysis of Packaging Tapes, *Proceedings 15th International Symposium of the ANZFSS, Gold Coast, March.*
  - Armitage S., Roux C., Robertson J., Day R., **Dawson M.**, (2000). New High Performance Liquid Chromatographic Method for the Analysis of Seized Ecstasy Samples, *Proceedings 15th International Symposium of the ANZFSS, Gold Coast, March.*
  - Armitage S., Van Haren T., Roux C., **Dawson M.**, (2000). Techniques for the Physical Profiling of Tablets Sold as Ecstasy – A Preliminary Study, *Proceedings 15th International Symposium of the ANZFSS, Gold Coast, March.*
  - Bull S., Roux C., **Dawson M.**, Lennard C., (2000). Organic Propellant and Explosives Analysis by LC/MS/MS – Preliminary Results, *Proceedings 15th International Symposium of the ANZFSS, Gold Coast, March.*
  - Kwok B., Maynard P., Roux C., **Dawson M.**, Royds D., (2000). Differentiation of Capsicum Spray and their Residues using Gas Chromatography – Mass Spectrometry, *Proceedings 15th International Symposium of the ANZFSS, Gold Coast, March.*
  - **Dawson, M.**, Robertson, J., Goulding, J. and Armitage S. (1999). An Australian Approach to Ecstasy profiling. International Association of Forensic Scientists, Los Angeles, USA, August 22 –28.
  - **Dawson, M.**, Kannangara, K., Maynard, P. and Williamson, K. (1999). Hydriodic acid/red phosphorous reduction of N,N-dimethyl-3-phenyl-3-hydroxypropylamine International Association of Forensic Scientists, Los Angeles, USA, August 22 -28
  - **Dawson, M.**, Sabha, M., Hodda, A. and Bisset, T. (1999). The analysis of cyanide in blood. International Association of Forensic Scientists, Los Angeles, USA, August 22 –28.
  - **Dawson, M.**, Swift, W., Mahe,r L. and Tosi, B. (1999) The physical and chemical analysis of street level heroin samples. International Association of Forensic Scientists, Los Angeles, USA, August 22 –28.
  - **Dawson, M.**, Zurzolo, V., Hodda, A. and Morrice, C. (1999) The determination of beta-hydroxybutyrate in urine. International Association of Forensic Scientists, Los Angeles, USA, August 22 –28.
  - **Dawson, M.**, Conn, C., and Smith, M., (1999) A study of the O-dealkylation of codeine using pyridinium hydrochloride. International Association of Forensic Scientists, Los Angeles, USA, August 22 –28.
  - **Dawson, M.** (1999). The Role of Universities in the Drug Debate. 10th International Conference on the Reduction of Drug Related Harm. Geneva, Switzerland March 22 – 25.
  - **Dawson, M.**, Conn, C., Delaforce, H. and Steer, J. (1996) "Profiling of impurities in methylenedioxymethamphetamine (MDMA; ecstasy) and related illicit drugs. 13th Australian and New Zealand International Symposium on the Forensic Sciences, Sydney, Australia, September 8 - 13.
  - Fryirs, B., Woodhouse, A., Huang, J., **Dawson, M.**, and Mather, L. (1996) "Determination of subnanogram concentrations of fentanyl in plasma by gas chromatography-mass spectrometry" Chromatography 96 Symposium and Exhibition. Sydney, Australia, July 9 - 11.
  - Walsh, K. P., McLaughlan, R. G. and **Dawson, M.** (1996). "Measurement of dissolved hydrogen and other gases to observe insitu microbial activity in contaminated aquifers" International Symposium on Environmental Chemistry and Toxicology. Sydney, Australia, July 14 - 18.

- **Dawson, M.**, Young, B. and Child, N., (1995). "Unforeseen environmental consequences of the unregulated phase-out of lead anti-knock compounds: The Australian experience". Second International Conference on Volatile Organic Compounds London, UK, 8 - 9th November 1995.
- Lorenzana, R. M, **Dawson, M.**, Lowry, J., Ketterer, M and Simmons, J (1995). Concomitant administration of intravenous <sup>206</sup>Pb to enable the simultaneous collection of oral and intravenous area-under-the-curve data for the determination of oral bioavailability of lead containing soil and slag in swine. Society of Toxicology, Annual Meeting, March 5 - 9, Baltimore, Maryland, USA.
- Young, B and **Dawson, M.** (1994). Continuous monitoring of ambient toxic air pollutants contributing to photochemical smog in Sydney's CBD. Chemeca '94, 22nd Australasian Chemical Engineering Conference, Perth, WA, 25-28th September.
- **Dawson, M.**, Young, B and Child, N (1994). Continuous monitoring of ambient toxic air pollutants contributing to photochemical smog in Sydney's CBD. 1994 Air Toxics Conference, Sydney, 10-11th August
- **Dawson, M.** Measuring toxic pollutants in real time (1993). Horizons of Science Forum, Chemistry, University of Technology, Sydney, Wednesday 7th July.

#### (iv) Government and/or Contract Reports

- Swift, W., Maher, L and **Dawson, M.** Heroin purity and composition: An analysis of street level samples in Cabramatta, NSW. National Drug and Alcohol Research Centre Technical Report No 79 (1999) ISBN 0 7334 0658 0
- Lorenzana, R. M, **Dawson, M.**, Lowry, J., Ketterer, M and Simmons and Poppenga, R. Bioavailability of arsenic and lead in environmental substrates. United States Environmental Protection Agency Publication Number EPA 910/R-96-002. February 1996.
- **Dawson, M.**, Gillespie, L. H, Klein P. B. and Turner A. G. Report entitled "Chemical pollutants on the Alexandra Canal and Cooks River", April 1993, submitted to the NSW Environmental Trusts, (39 p).

#### (v) Confidential Contract Reports

- 42 in total over the period 1991 –2002.

#### (vi) Other public output

##### PRINT MEDIA

- 59 opinion pieces or other newspaper articles over the period 1991 – 2002.

##### TELEVISION

- 8 television interviews on news and current affair programs over the period 1993 – 2002.

##### RADIO

- 15 radio interviews over the period 1993 – 2001.

## **APPENDIX B – CURRICULUM VITAE OF DR WODAK**



## Curriculum Vitae

ALEX WODAK

### QUALIFICATIONS:

MBBS (University of Melbourne,  
St. Vincent's Hospital Clinical School).  
Graduated in 1970 with honours in Medicine, Surgery, and Pathology.

MRACP (Royal Australasian College of Physicians) 1974.

FRACP (Royal Australasian College of Physicians) 1978.

MRCP (Royal College of Physicians, London) 1980.

FAFPHM (Royal Australasian College of Physicians) 1991.

FChAM (Royal Australasian College of Physicians) 2003.

### 1. EMPLOYMENT:

- 1982 - Director, Alcohol and Drug Service  
St Vincent's Hospital
- 1982 - 1994 Member, Bruce Hall Gastroenterology Department,  
St Vincent's Hospital, Sydney, New South Wales, Australia.
- 1980 - 1982 Research Fellow (Honorary Senior Registrar), Liver Unit, Kings College Hospital,  
London.
- 1978 - 1980 Medical Registrar, Central Middlesex Hospital.
- 1976 - 1977 Medical Registrar, University College Hospital, London.
- 1973 - 1975 Medical Registrar, St. Vincent's Hospital, Melbourne.
- 1972 - 1973 Senior Resident, St. Vincent's Hospital, Melbourne.
- 1971 - 1972 Junior Resident, Alfred Hospital, Melbourne.

## 2. APPOINTMENTS:

- 1985-1993 Conjoint Lecturer, School of Medicine, UNSW
- 1991 - Conjoint Lecturer, (1991 -1993), Conjoint Senior Lecturer, (1993-1997)  
National Drug and Alcohol Research Centre, University of New South Wales
- 1992 -1998 Conjoint Research Fellow, National Centre in HIV Epidemiology and Clinical  
Research, University of New South Wales
- 1993 - Conjoint Senior Lecturer, School of Medicine, UNSW
- 1994 - Conjoint Senior Lecturer, School of Community Medicine, UNSW
- 1999 - Honorary Visiting Fellow, National Centre in HIV Epidemiology and Clinical Research,  
University of New South Wales

## 3. COMMITTEE MEMBERSHIP:

- 1983 - 1989 Member, Drug Committee, St. Vincent's Hospital.
- 1983 - 1985 Honorary Secretary, Australian Medical Society on Alcohol and Drugs.  
(AMPSAD)
- 1983 - 1995 Council member, Australian Medical Society on Alcohol and Drugs. (AMPSAD)
- 1985 -1992, 1994- Member, Medical Committee under the New South Wales Poison's  
Act. (1966). (Representative of the Royal Australasian College of Physicians).
- 1984 - 1987 Member, Methadone Standing Committee, New South Wales Department of Health.
- 1985 - 1987 Chairman, Bruce Hall Gastroenterology Department, St. Vincent's Hospital.
- 1986 - 1987 Member, Methadone Sub-Committee of Medical Committee under the  
Poison's Act.
- 1986 - 1987 Member, Management Committee, National Drug and Alcohol Research  
Centre, Sydney.
- 1986 - 1987 Member, Research Committee, National Drug and Alcohol Research Centre,  
Sydney.
- 1986 - 1991 Member, Steering Committee, Drug Education Project, ("Get Real"). Chairman, (1989 -  
91).
- 1986 - 1989 Member, New South Wales Department of Health AIDS and Intravenous Drug  
Use Sub-committee.

- 1986 - 1990 Member, Standing Committee on AIDS and Intravenous Drug Use, National Advisory Committee on AIDS (NACAIDS); later Australian National Council on AIDS (ANCA).
- 1987 - Member, Ministerial Advisory Committee on AIDS (New South Wales)
- 1987 - 1995 Working Party on Alcohol and Health, Royal Australasian College of Physicians. Chairman (1988 -95 ).
- 1988 - 1994 Methadone Policy Committee (New South Wales).
- 1989 - 1991 Member, Director's Advisory Committee, National Drug and Alcohol Research Centre, Sydney.
- 1989 - 1990 Immediate Past President, Committee Member, Australasian Society for HIV Medicine (ASHM).
- 1991 - 1992 Board Member, Australian Council on Alcohol and other Drugs (ACAD)
- 1992- 1992 Member, (Australian) Alcohol Policy Advisory Council
- 1993- Member, Board of Advisors, the Drug Policy Foundation, Washington DC, USA.
- 1994- Chairman, Medical Committee under the New South Wales Poison's Act. (1966).
- 1996- President, Australian Drug Law Reform Foundation
- 1997-1999 Member, Australian National Council on AIDS and Related Diseases (ANCARD)
- 1998-2004 Member, National Alcohol Strategy Committee (later called the National Expert Advisory Committee on Alcohol)
- 1998-2000 Member, Hepatitis C Sub-committee of ANCARD
- 1998- Member, Research Advisory Committee, ANCARD
- 1998- Member, NHMRC Working Party on the Review of Recommendations Regarding Responsible Drinking Behaviour
- 1999 Corrections Health Service Clinical Council
- 2000 Member, Australian National Council on AIDS, Hepatitis C and Related Diseases (ANCHARD) Hepatitis C Sub Committee
- 2002 Local: Kings Cross Community Drug Action Team (CDAT)
- State: Chair, Medical Committee Under the NSW Poison's Act (1966)  
NSW Ministerial Advisory Committee on AIDS Strategy

NSW Ministerial Advisory Committee on Hepatitis  
NSW Corrections Health Research Ethics Committee

Commonwealth:

National Expert Advisory Committee on Alcohol  
NHMRC Guidelines for Responsible Drinking  
Smoking, Nutrition, Alcohol and Physical Inactivity (SNAP) in General Practice  
Hepatitis C Subcommittee of the Australian National Council on HIV/AIDS and Related Diseases

National: President, Australian Drug Law Reform Foundation  
Working Party to establish a Chapter of Addiction Medicine, RACP

International

President, International Harm Reduction Association  
Co-chair: Global Research Network (founded by NIDA and WHO)

#### 4. CONSULTANCIES:

1987 - Associate Consultant, Peat, Marwick, Mitchel Management Consultants, in preparation of a Youth Drug Strategy for the Office of Youth Affairs, Department of The Prime Minister and Cabinet.

1989 - Short Term Consultant, Global Programme on AIDS, World Health Organisation Geneva (1 September 1st – 6 October).

1990 Short Term Consultant, Global Programme on AIDS, World Health Organisation Geneva, Mission to Myanmar, May

1990 Short Term Consultant, World Health Organisation, Western Pacific Region, Kuala Lumpur, HIV/AIDS and injecting drug users in SE Asia.

1990 Short Term Consultant, Global Programme on AIDS World Health Organisation, New Delhi, Mission to Sri Lanka, December

1991 Inter-regional Meeting, World Health Organisation, Tokyo, The Prevention of Alcohol Related Problems, April

1993 National AIDS Programme, Brazil, "Train the Trainers" workshop on the prevention of HIV among and from injecting drug users.

1994 National AIDS Programme, Nepal, Workshop on Indigenous Harm Reduction Strategies for the prevention of HIV among injecting drug users in Developing Countries.

1994 Mental Health Coding and Classification Clinical Group, Australian Casemix Clinical Committee.

## 5. MEMBERSHIP OF SPECIAL SOCIETIES:

Royal Australasian College of Physicians (RACP)  
The Australian Professional Society on Alcohol and Drugs (APSAD)  
The Public Health Association of Australia (PHA)  
The Australasian Society of HIV Medicine (ASHM)  
The International AIDS Society (IAS)  
The Alcohol and other Drugs Council of Australia (ADCA)  
The Australian Drug Law Reform Foundation

## 6. AWARDS

Norman Zinburg Award for Medicine, 1992: Drug Policy Foundation, Washington DC, USA.

Rolleston International Award, 1994. Sixth International Conference on the Reduction of Drug Related Harm. Toronto, Canada.

NSW Public Health Association Impact Award 2001

Royal Australasian College of Physicians, Caughey Medal, 11 May, 2005

## 7. SUPERVISION:

Completed:

Master of Health Administration thesis "Changes in Knowledge, Attitudes, and Risk-taking Behaviour of Sydney Intravenous Drug Users in Relation to AIDS" (Ms J Wolk).

PhD (Community Medicine and Psychology) on "Cognitive Behavioural Interventions to reduce HIV risk taking behaviours in Injecting Drug Users". (Dr. A. Baker). 1994

PhD (Community Medicine) "HIV risk taking behaviours in Injecting Drug Users in prison". (Dr.K.Dolan) 1999.

PhD Epidemiology (Community Medicine) "Monitoring and surveillance of blood borne viruses in injecting drug users." Dr. M. MacDonald. 2002

## 8. REVIEWER:

Applications for research grants submitted to the National Health and Medical Research Council, Commonwealth Department of Health, and Health promotion Foundations in Victoria and Western Australia.

## 9. CONFERENCES, SEMINARS AND WORKSHOPS ORGANISED:

- 1984 Member of the Programme and Organising Committee for the Fourth Annual Conference of AMSAD. "Alcohol Control Policies". Sydney.
- 1986 Programme Committee, 8th International Federation of Non-Government Alcohol and Drug Organisations Conference, Sydney.
- 1986 Convenor of a National Cocaine Treatment Workshop, Sydney.
- 1986 The effect of low doses of alcohol; alcohol and the cardiovascular system; alcohol and the gastrointestinal system. Sessions of the Sixth National Conference of AMSAD, Perth.
- 1987 Organising Committee, Conference of Tertiary Educators on Alcohol and Drugs.
- 1989 Organising Committee, International Conference on the Treatment of Addictive Behaviours (ICTAB-V).
- 1989 Programme Committee, Tenth National Conference of the Australian Medical Society on Alcohol and Drugs.
- 1989 National Medical Scientific Conference on AIDS.
- 1990 Chairman, Programme Committee, National Conference, Australian Medical Society on Alcohol and Drugs
- 1991 Chairman, Programme Committee, Third International Conference on the Reduction of Drug Related Harm, Melbourne, March, 1992.
- 1992 Programme Committee for the National Methadone Conference, Sydney, March, 1992.
- 1993 Chairman, Organising Committee, National Conference Public Health Association
- 1994 Programme Committee for the National Methadone Conference, Sydney, November, 1994.
- 1996 Chairman, Programme Committee, Seventh International Conference on the Reduction of Drug Related Harm, Hobart, March 3-7, 1996
- 1997 Member Steering Committee, Chairman Public Health Stream, First Australasian Conference on Hepatitis C, Sydney, March 16-18, 1997
- 1997 Member, Australian National Council on AIDS and Related Diseases; Research Advisory Committee of the Australian National Council on AIDS and Related Diseases; Hepatitis C sub Committee of the Australian National Council on AIDS and Related Diseases.

- 1998 Member, NHMRC Working Party on the Review of Recommendations Regarding Responsible Drinking Behaviour.
- 1999 Member, Executive Committee, WHO/NIDA International Network of Researchers on spread of HIV among Injecting Drug Users.
- 2000 Member, Programme Committee, National Conference, Australian Professional Society on Alcohol and Drugs.
- 2001 Member, Executive Programme Committee, Fourteenth International Conference on the Reduction of Drug Related Harm, Chiang Mai, April 6-10, 2001

#### 10. CURRENT POSITION:

(1) Medical care of inpatients and outpatients with complications of alcohol and drug dependence; supervision of a registrar; overall responsibility for the Alcohol and Drug Service, St. Vincent's Hospital. This department has over 50 staff and an annual budget of over \$4 million.

Supervised activities include:

- (2) Non-medical detoxification, 13 staff, 20 beds, over 3,000 admissions per year.
- (3) Telephone counselling, about 70,000 calls per year.
- (4) Assessment and referral for a 350-bed hospital and 160,000 population, four counsellors.
- (5) Methadone Stabilisation Clinic (340 patients)
- (6) Out patient medical detoxification

#### 11. TEACHING:

Lectures and tutorials to medical students on alcohol and drugs, drug overdose, University of New South Wales and St. Vincent's Hospital.

Lectures to Masters of Public Health students (University of NSW and University of Sydney).

#### 12. CURRENT SPECIAL PROJECTS:

- 1) HIV/AIDS, Injecting Drug Use, Developing Countries:

I have conducted workshops, given invited papers at conferences or provided consultancies in a number of developing countries on controlling HIV among injecting drug users (including Nepal, India, Pakistan, Bangladesh, Vietnam, Indonesia, Thailand, China, Brazil, Argentina, Egypt, Iran) to encourage

adoption of harm reduction approaches to the spread of blood borne viral infections among injecting drug users.

2) Drug Policy Reform:

I became interested in drug policy after my involvement in the establishment of the first needle exchange in Australia in 1986. After visiting the United States in 1987 on sabbatical leave, my interest intensified. I have attended a number of annual meetings of the Drug Policy Foundation in Washington DC and took part in the establishment of the Australian Parliamentary Group for Drug Law Reform and the subsequent formation of the Australian Drug Law Reform Foundation. In 1995, I co-authored a book for UNSW Press on drug policy reform. In 1996, I became President of the Australian Drug Law Reform Foundation

**13. COLLEGES:**

Royal Australasian College of Physicians (RACP).  
 Australasian Faculty of Public Health Medicine  
 Royal College of Physicians (London)  
 Chapter of Addiction Medicine, RACP

**14. JOURNAL PUBLICATIONS:**

- (1) Wodak AD, Saunders JB, Williams R. Alcoholism: What Can The Occupational Health Service Do? Occupational Health. 1981; 33: 548-553.
- (2) Wodak AD, Richardson PJ. Alcohol and the Cardiovascular System. Brit J Addict. 1982; 251-8.
- (3) Saunders JB, Wodak AD, Haines A, Powell-Jackson PR, Portmann B, Davis M, Williams R. Accelerated Development of Alcoholic Cirrhosis in Patients with HLA-B8. Lancet 1982; I: 1381-1384.
- (4) Richardson PJ, Atkinson A, Wodak A. The measurement of enzyme activities in endomyocardial biopsies from patients with congestive (dilated) cardiomyopathy and specific heart muscle disease. Zeitschrift Fur Kardiologie- Z Kardiol 1982; 71: 522-6.
- (5) Wodak AD, Saunders JB, Ewusi-Mensah I., David M, and Williams R. Severity of Alcohol Dependence in Patients with Alcoholic Liver Disease. Br Med J 1983; 287:1420-1422.
- (6) Wodak AD. The Role of the Hospital Unit. Australian Alcohol/Drug Review 1983; 2 (2): 9-10.
- (7) Wodak AD, De Burgh SPH. Alcohol Control Policies. Australian Alcohol/Drug Review 1983; 2 (2): 68 - 75.
- (8) Saunders JB, Wodak AD, Morgan-Capner P, White YS, Portmann B, Davis M, Williams R. Importance of Markers of Hepatitis B virus in Alcoholic Liver Disease. Br Med J 1983; 286: 1851-1854.



- (9) Ewusi-Mensah I, Saunders JB, Wodak AD, Murray RM Williams R. Psychiatric Morbidity in Patients with Alcoholic Liver Disease. *Br Med J* 1983; 287: 1417-1419.
- (10) Wodak, AD, Baldwin R. Comment on "The Doctor and the Drug Addict" *Med J Aust* 1983; 234.
- (11) Wodak AD. "Action on Alcohol Abuse" *Med J Aust* 1984; 1:177.
- (12) Wodak AD. Buprenorphine, New Wonder Drug or New Hazard? *Med J Aust* 1984; 140 (7): 389-90. (Editorial).
- (13) Wodak AD. Responding to Alcohol and Drug Problems. *Australian Alcohol/Drug Review* 1984; 3 (1): 10-13.
- (14) Wodak AD. Alcohol and Drug Responses - Treatment or Prevention? Proceedings of the Autumn School of Alcohol and Drug Studies, St. Vincent's Hospital, Melbourne. 1984.
- (15) Saunders JB, Wodak AD, Williams R. What determines susceptibility to liver damage from alcohol? *JRoyal Society Med* 1984; 77: 204-216.
- (16) Cooper DA, Wodak A, Marriott DJE, Harkness JL, Ralston M, Hill A, Penny R. Cryptosporidiosis in the acquired immune deficiency syndrome. *Pathology* 1984; 16: 455-457.
- (17) Saunders JB, Wodak AD, Williams R. Past Experience of Advice and Treatment for Drinking Problems of Patients with Alcoholic Liver Disease. *Brit J Addict* 1985; 80: 51-56.
- (18) Wodak A. The Treatment of Heroin Dependence - An Overview. Proceedings of the Institute of Criminology Drugs and Crime. The University of Sydney, Faculty of Law. 1985; 65: 27 - 44.
- (19) Blacker P, Tindall B, Wodak AD, and Cooper D. Exposure of Intravenous Drug Users to AIDS Retro Virus Sydney, 1985. *Aust NZ J Med*; 1986; 16 (5): 686-690.
- (20) Wodak, AD. Australian Alcohol Consumption. *Med J Aust* 1986; 144: 1-2. (Editorial).
- (21) Richardson PJ, Wodak AD, Atkinson L, Saunders JB, Jewitt DE. Relationship between alcohol intake, myocardial enzyme activity and myocardial function in dilated cardiomyopathy: evidence for the concept of alcohol induced heart muscle disease. *Br Heart J* 1986; 56 (2): 165-170.
- (22) Wodak A, Gold J, HIV antibodies in intravenous drug abusers. *Med J Aust* 1986; 145:298.
- (23) Wodak AD. A Report on the AMSAD National Workshop on Clinical Responses to Cocaine, Sydney, September. 1986.
- (24) Mant A, Wodak A, Day R. Benzodiazepine Dependence: Strategies for Prevention and Withdrawal. *Current Therapeutics*. February 1987; 59-79.

- (25) Reilly DK, Ray JE, Day RO, Wodak AD, O'Connor D, Thompson J. Classification of Overdose/Self Poisoning Presentations to an Accident and Emergency Department. *International Journal of Addiction*. 1987; 22: 941-955.
- (26) Wodak AD. Street Drugs: Clinical aspects and management. *Australian Family Physician* 1987; 16 (1): 15-19.
- (27) Wodak A, Dolan K, Imrie A, Gold J, Wolk J, Whyte B, & Cooper DA. Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. *Med J Aust* 1987; 147: 275.
- (28) Wodak A. Automobile wagons, alcohol ... and drugs. *Med J Aust* 1987; 147: 3-5.
- (29) Wodak A. Our Daily Fix - Drugs in Australia. *Community Health Studies* 1987; XI (2): 147-148.
- (30) Wodak A. The Metabolism and Effects of Alcohol. *NSW Psychopharmacology Newsletter Vol 1, No. 2., 1987*. Editor E. Freed.
- (31) Wodak A. Cannabis: Facts at Your Fingertips. *Current Therapeutics* 1988; 29 (4): 13-17.
- (32) Wodak AD, Drug and Law Policy. *The Australian Journal of Forensic Sciences*. 1988; 21 (i): 34-37.
- (33) Wodak Alex, Penny Ronald. A report on the National Advisory Committee on Acquired Immunodeficiency Syndrome's workshop on human immunodeficiency virus infection and intravenous drug abuse. *Med J Aust*. 1988; 149: 373-375.
- (34) Wodak A, Whyte BM. AIDS and Intravenous Drug Users in Australia. *AIDS and Public Policy Journal*. 1988; 3 (2): 47-49.
- (35) Wolk J, Wodak A, Morlet A, Guinan J, Wilson E., Gold J, and Cooper D. Syringe HIV seroprevalence and behavioural and demographic characteristics of Intravenous drug abusers using syringe exchanges in Sydney, Australia, 1987. *AIDS* 1988; 2: 373-378.
- (36) Wodak A. Legal and illegal drugs: Targeting the right enemy. (Editorial) *Australian Drug and Alcohol Review*. 1989; 8 (1): 8:1-3.
- (37) Wodak AD. Love, Latex and the Future. *Modern Medicine*. 1989; 32 (2): 74-76.
- (38) Wodak AD. "Alcohol and drugs - past and future." *Modern Medicine* 1989; 32 (6): 18-31.
- (39) Wodak Alex. "Diagnosing the Problem drinker", *Australian Medicine* 1989; 1 9: 206-207.
- (40) Wodak, Alex. "Developments on National Drug Policy in Australia". *The International Journal on Drug Policy* 1989; 1 (1): 11-12.

- (41) Wodak A. Patient Management - Drying out the demon drinker. *Australian Medicine* 1989; 1: 234-235.
- (42) Wodak A, Richmond R, Wilson A. Thiamin fortification and alcohol. *Med J Aust* 1990; 152: 97-99.
- (43) Wodak A. Alcohol and Women's Health: Cause for concern? *Healthright* 1990; 9 (3): 17 - 22.
- (44) Wodak A. Heroin legalisation: totem and taboo revisited. *Modern Medicine* 1990; 33 (5): 76 - 95.
- (45) Wolk J, Wodak A, Morlet A, Guinan JJ, Gold J. HIV-related risk-taking behaviour, knowledge and serostatus of intravenous drug users in Sydney. *Med J Aust* 1990; 152: 453-458.
- (46) Edwards P, Wodak A, Cooper DA, Thompson IL, and Penny R. The Gastroenterological Manifestation of AIDS. *Aust NZ J Medicine* 1990; 20 (2): 141-148.
- (47) Wodak A, McArthur T, Carroll T. Drug and AIDS Education for Australian Youth: The Get Real Project. *Hygie International Journal of Health Education* 1990; IX: 8-10.
- (48) Wodak A. Alcoholism - what can the GP do? *Modern Medicine* 1990; 33 (7): 86 - 94.
- (49) Wodak A. Put Your Question: How do I get through the denial used by alcoholics? *Patient Management* 1990; 19 (10): 59.
- (50) Wodak A, The Connection between HIV infection in injecting drug users and drugs policy. *The International Journal on Drug Policy* 1990; 1 (6): 22-23.
- (51) Wolk J, Wodak A, Guinan J, Macaskill P, Simpson JM. The Effect of a Needle and Syringe Exchange on a Methadone Maintenance Unit. *Brit J Addict* 1990; 85: 1445 -1450.
- (52) Wodak AD. The never-ending story. *Drug and Alcohol Review* 1990; 9 (4): 346-350.
- (53) Wodak AD, Monheit BM. Methadone. *Med J Aust* 1990; 153: 742.
- (54) Wodak A, Moss A. HIV infection and intravenous Drug users: from epidemiology to public health. *AIDS* 1990; 4 (suppl. 1): S 105-S109.
- (55) Chesher G, Wodak A. Evolving a New Policy for Illicit Drugs. *Journal of Drug Issues* 1990; 20 (4): 555-561.
- (56) Darke S, Heather N, Hall W, Ward J, and Wodak A. Estimating drug consumption in opioid users: Reliability and Validity of a "recent use" episodes methods. *Brit J Addict.* 1991; 86: 1311-1316.
- (57) Wodak A. A wider view of alcohol consumption in Australia. 1 The social cost. *Med J Aust.* 1991; 154: 838-839.

- (58) Wodak A. Recent Advances in Alcohol and Drug Research. *The Australian Journal of Psychopharmacology* 1991; 5: 17-18.
- (59) Wodak A. "Why the war against drugs has failed". *Med J Aust.* 1991; 155: 37-38.
- (60) Wodak A. I feel like an alcohol advertisement. (Editorial). *Australian Journal of Public Health.* 1991;15 (3):170-171.
- (61) Ross MW, Gold J, Wodak AD, Miller ME. Sexually transmissible diseases in injecting drug users. *Genitourinary Medicine* 1991; 67 (1): 32-36.
- (62) Darke S, Hall W, Heather N, Ward J, Wodak A. The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. *AIDS* 1991; 5: 181-185.
- (63) Wodak A. Helping a medical colleague with a drinking or drug problem. *Modern Medicine* 1991; 34 (12): 22-23.
- (64) Wodak A. Preventing HIV spread among injecting drug users. *Lancet* 1991; 337: 482.
- (65) Darke S, Baker A, Dixon J, Wodak A, Heather N. Drug use and HIV risk-taking behaviour among clients in methadone maintenance treatment. *Drug and Alcohol Dependence* 1992; 29: 263-268.
- (66) Ross MW, Wodak A, Gold J, Miller ME. Differences across sexual orientation on HIV risk behaviours in injecting drug users. *AIDS Care.* 1992; 4 (2):139-148.
- (67) Carey DL, Day RO, Cairns DR, Pearce GA, Wodak AD, Lauchlan RL. An attempt to influence hypnotic and sedative drug use. *Med J Aust.* 1992; 156: 389-393.
- (68) Stowe A, Wodak A, Ross MW. Contact between injecting drug users and general practitioners and its implications for health education. *J Roy Soc Health* 1992; 112 (3): 122-123.
- (69) Wodak, A. Taming demons: the reduction of Harm resulting from use of illicit drugs. *Aust NZ J Med* 1992; 22: 204-208.
- (70) Wodak A. The dismal science and our favourite drug. (Editorial) *Med J Aust* 1992; 156: 747-748.
- (71) Wodak A. The epidemic that Australia does not have to have. *Today's Life Sciences.* 1992; 4 (6): 26-30.
- (72) Wodak A. She who pays the piper calls the tune. (Editorial). *Drug and Alcohol Review.* 1992; 11: 107-109.
- (73) Wodak A. Controlling HIV infection behind bars: Questions, Strategies and Obstacles. *Current Issues in Criminal Justice.* 1992; 4 (11): 28-36.

- (74) Wodak A. HIV infection and injecting drug use in Australia: responding to a crisis. *Journal of Drug Issues* 1992; 22 (3): 549-562.
- (75) Ross MW, Wodak A, Gold J. The association of needle cleaning with reduced seroprevalence among injecting drug users sharing injection equipment. *Journal of Acquired Immunodeficiency Syndromes* 1992; 5 (8): 849-850 (Letter to the Editor)
- (76) Ross MW, Buzolic A, Wodak A, Stowe A, Gold J, Miller ME. Structure and measurement of dimensions of risk for HIV transmission in injecting drug users. *Drug and Alcohol Review* 1992; 11: 231-237.
- (77) Barber JG, Ross MW, Wodak A, Miller ME, Gold J. The social behaviour of intravenous drug users. *British Journal of Social Work* 1992; 22: 455-462.
- (78) Ross MW, Chapman S, Wodak A, Miller ME, Gold J. Media sources of HIV/AIDS information in injecting drug users. *Australian Journal of Public Health* 1992; 16 (3): 324-7.
- (79) Darke S, Hall W, Ross MW, Wodak A. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. *Drug and Alcohol Dependence* 1992; 31: 31-36.
- (80) Darke S, Hall W, Heather N, Wodak A, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opioid users: the Opiate Treatment Index. *Brit J Addict* 1992; 87: 593-602.
- (81) Darke S, Wodak A, Hall W, Heather N, Ward J. Prevalence and predictors of psychopathology among opioid users. *Brit J Addict* 1992; 87: 771-776.
- (82) Ross MW, Wodak A, Gold J. Sexual behaviour in injecting drug users. *Journal of Psychology and Human Sexuality* 1992; 5: 89-104.
- (83) Ross MW, Stowe A, Loxley W, Wodak AD. "Home bake" heroin use by injecting drug users. [letter] *Med J Aust* 1992; 157 (4): 283-284.
- (84) McLachlan C, Crofts N, Wodak A, Crowe S. The effects of methadone on immune function in injecting drug users: a review. *Addiction* 1993; 88 (2): 257-263.
- (85) Wodak A. HIV infection in drug and alcohol practice. *Med J Aust* 1993; 158: 266.
- (86) Baker A, Heather N, Wodak A, Dixon J, Holt P. Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. *AIDS*. 1993; 7 (2): 247-256.
- (87) Friedman SR, De Jong W, Wodak A. Community development as a response to HIV among drug injectors. *AIDS*. 1993; 7 (suppl. 1): S 263-S 269.
- (88) Hall W, Darke S, Ross MW, Wodak A. Patterns of drug use and risk-taking among injecting opioid and amphetamine drug users in Sydney, Australia. *Addiction* 1993; 88 (4): 509-516.

- (89) Wodak A, Des Jarlais DC. Strategies for the prevention of HIV infection among and from injecting drug users. *Bulletin on Narcotics*. 1993; 45 (1): 47-60.
- (90) Ross MW, Wodak A, Gold J. Accuracy of self-reporting of sexually transmissible disease in injecting drug users. *Journal of the European Academy of Dermatology and Venereology*. [letter] 1993; 2: 147-148.
- (91) Wodak A, Hawks DV. Here's to your health? (Editorial) *Aust NZ J Med* 1993; 23: 242-3.
- (92) Wodak A, Fisher R, Crofts N. HIV infection among injecting drug users in Asia: an evolving public health crisis: *AIDS Care* 1993; 5 (3): 315-322.
- (93) Ross MW, Stowe A, Wodak A, Miller ME, Gold J. A comparison of drug use and HIV infection risk behaviour between injecting drug users currently -in treatment, previously -in -treatment, and never-in treatment. *Journal of Acquired Immunodeficiency Syndromes* 1993; 6: 518-528.
- (94) Gaughwin M, Kliewer E, Ali R, Faulkner C, Wodak A, Anderson G. The prescription of methadone for opiate dependence in Australia, 1985-1991. *Med J Aust* 1993; 159: 107-108.
- (95) Ross MW, Wodak A, Miller ME, Gold J. Sexual partner choice in injecting drug users from a "critical incident" measure: its implications for assessing risk of HIV spread. *Sexological Review*. 1993; 1 (1): 77-92.
- (96) Crisp BR, Barber JG, Ross MW, Wodak A, Gold J, Miller M.E. Injecting Drug Users and HIV/AIDS: risk behaviours and risk perception. *Drug and Alcohol Dependence*. 1993; 33 (1): 73-80.
- (97) Wodak A. To take up arms against a sea of drugs. *The Journal of Contemporary Health Law and Policy*. 1993; 9: 323-335.
- (98) Kaldor J, Elford J, Wodak A, Crofts JN, Kidd S. HIV prevalence among IDUs in Australia: a methodological review. *Drug and Alcohol Review*. 1993; 12: 175-184.
- (99) Ross MW, Loxley W, Wodak AD, Buzolic A, Monheit B, Stowe A. Drug users' self-reported false-positive HIV status [letter]. *Amer J Pub Health* 1993; 83: 1349-1351.
- (100) Ross MW, Stowe A, Wodak A, Gold J. Changes in equipment sharing in injecting drug users in Sydney 1989-1990. *Drug and Alcohol Review*. 1993; 12: 277-281.
- (101) Caplehorn JRM, Reilly DK, Wodak A. Detected Heroin use in an Australian Methadone Maintenance Program. *Journal of Substance Abuse Treatment* 1993; 10 (6): 553-559.
- (102) Wodak A. Preventing the spread of HIV among Australian injecting drug users. *Forensic Science International*. 1993; 62: 83-87.
- (103) Stowe A, Ross MW, Wodak A, Thomas GV, Larson SA. Significant relationships and social supports of injecting drug users and their implications for HIV/AIDS services. *AIDS Care* 1993; 5 (1): 23-33.

- (104) Ross MW, Kelaher M, Wodak A, Gold J. Predictors of intoxicated sex among injecting drug users. *Journal of Addictive Diseases* 1994; 13 (2): 69-80.
- (105) Wodak A. Managing illicit drug use: a practical guide. *Drugs*. 1994; 47 (3): 446-457.
- (106) Ross MW, Stowe A, Wodak A, Miller ME, Gold J. Predictors of HIV status among injecting drug users and health promotion. *J Roy Soc Health* 1994; 114 (2): 75-80.
- (107) Wodak A. How do communities achieve reductions in alcohol- and drug-related harm? *Addiction*. 1994; 89; 147-150.
- (108) Ross MW, Wodak A, Stowe A, Gold J. Explanations for sharing injection equipment in injecting drug users and barriers to safer drug use. *Addiction* 1994; 89: 473-479.
- (109) Baker A, Kochan N, Dixon J, Wodak A, Heather N. Drug use and HIV risk-taking behaviour among injecting drug users not currently in treatment in Sydney. *Drug and Alcohol Dependence* 1994; 34; 155-160.
- (110) Crisp BR, Barber JG, Ross MW, Wodak A, Gold J, Miller ME. Predictors of unsafe injecting drug use. *Drug and Alcohol Review*. 1994; 3: 13-19.
- (111) Day R, Chesher GB, Wodak A. Cannabis and suicide. *Med J Aust* (letter) 1994; 160: 731.
- (112) Dolan K, Hall W, Wodak A, Gaughwin M. (letter) Evidence of HIV transmission in an Australian prison. *Med J Aust* 1994; 160: 734.
- (113) Wodak A. Comments on Ball and van de Wijngaart's article "A Dutch addict's view of methadone maintenance-an American and a Dutch appraisal" Olympian ideas or pragmatism? (Commentary) *Addiction*. 1994; 89: 803-814.
- (114) Wodak A. Just say "no" to alcohol abuse and misuse. (Editorial) *Addiction*. 1994; 89: 787-790.
- (115) Wodak A, Dolan K. (letter) Evidence of HIV transmission in an Australian prison. *Med J Aust* 1994; 161: 509.
- (116) Wodak A, Dolan K. A tale of three viruses. *Today's Life Sciences*. 1994; 6 (7): 60-64.
- (117) Wodak A, Crofts N. HIV revisited: preventing the spread of blood borne viruses among injecting drug users. *Australian Journal of Public Health* (Editorial) 1994; 18 (3): 239-241.
- (118) Wodak A. Whose Territory Is It Anyway? Should Psychiatry Own Alcohol And Drugs In Australia? *The Australian and New Zealand Journal Of Psychiatry*. (Editorial) 1994; 28 (3): 375-377.
- (119) Wodak A. Recent advances in alcohol and drugs. *Med J Aust*. 1994; 161: 566-568.
- (120) Dwyer R, Richardson D, Ross MW, Wodak A, Miller ME, Gold J. A comparison of HIV risk between women and men who inject drugs. *AIDS Education and Prevention* 1994; 6 (5): 379-89.

- (121) Baker A, Kochan N, Dixon J, Heather N, Wodak A. Controlled evaluation of a brief intervention for HIV prevention among injecting drug users not in treatment. *AIDS Care* 1994; 6 (5): 559-570.
- (122) Wodak A. Conditions and diseases other than cardiovascular associated with moderate alcohol consumption. *Contemporary Drug Problems*. 1994; Spring: 101-109.
- (123) Richmond R, Heather N, Wodak A, Kehoe L, Webster I. Controlled evaluation of a general practice-based brief intervention for excessive drinking. *Addiction* 1995; 90: 119-132.
- (124) Wodak A. The world illicit drug crisis: from prohibition to reform. *The International Journal of Drug Policy*. 1995; 5 (4): 218-220.
- (125) Baker A, Kochan N, Dixon J, Wodak A, Heather N. HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone maintenance treatment in Sydney, Australia. *Addiction* 1995; 90: 545-554.
- (126) Wodak A, Caplehorn JRM, Crofts N. Understanding gender differences in psychosocial functioning and treatment retention. *Amer J Drug Alcohol Abuse (letter)* 1995; 21 (2): 267-281.
- (127) Wodak A. A practical guide to managing illicit drug use. *Practical Therapeutics*. 1995; 36(8), 71-78.
- (128) Wodak A, Stowe A, Ross MW, Gold J, Miller ME. HIV risk exposure of injecting drug users in Sydney. *Drug and Alcohol Review*. 1995; 14 (2): 213-222.
- (129) Dolan K, Wodak A, Penny R. AIDS behind bars: preventing HIV spread among incarcerated drug injectors. (Editorial). *AIDS* 1995; 9: 825-832.
- (130) Wodak A. (1995) Painful lessons: opioids, iatrogenic dependence and professional standards. *Med J Aust (Editorial)* 1995; 163 (4): 174.
- (131) Wodak A, Saunders W. Harm Reduction Means What I Choose It To Mean. (Editorial) *Drug and Alcohol Review* 1995; 14: 269-271.
- (132) Des Jarlais DC, Hagan H, Friedmann SR, Friedman P, Goldberg D, Frischer M, Green S, Tunvig K, Ljungberg B, Wodak A, Ross M, Purchase D, Millson ME, Myers T. Maintaining Low HIV Seroprevalence in populations of injecting drug users. *JAMA* 1995; 274: 1226-1231.
- (133) Ross MW, Stowe A, Wodak A, Gold J. Reliability of interview responses of injecting drug users. *Journal of Addictive Diseases* 1995; 14: 1-12.
- (134) Wodak A. Harm reduction: Australia as a case study. *Bull NY Acad Med Winter* 1995; 339-347.
- (135) Wodak A, Crofts N. Once more unto the breach: controlling hepatitis C in injecting drug users. *Addiction* 1996; 91 (2): 181-184.



- (136) Dolan K, Rutter S, Wodak A, Hall W, Maher L, Dixon D. Is syringe exchange feasible in a prison setting? [letter]. *Med J Aust* 1996; 164: 508.
- (137) Byrne A, Wodak A. Census of patients receiving methadone maintenance treatment in a general practice. *Addiction Research* 1996; 3 (4): 341-349.
- (138) Dolan K, Wodak A. An international review of methadone provision in prison. *Addiction Research* 1996; 4 (1): 85-97.
- (139) Wodak A. Helping injecting drug users. What can general practitioners do? *Current Therapeutics*. 1996; 37 (7): 13-16.
- (140) Wodak A, van Beek I. HIV and injecting drug use. *Med J Aust* 1996; 165: 39-40.
- (141) Dolan K, Wodak A, Rutter S. Is a syringe exchange feasible in a prison setting? [letter]. *Med J Aust* 1996; 165: 59.
- (142) Wodak A. Commentary on the ACT heroin trial: when medical research is beholden to politics. *Med J Aust* 1996; 164: 649-650.
- (143) Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. [letter]. *Brit Med J* 1996; 312: 1162.
- (144) Richmond R, Kehoe L, Heather N, Wodak A, Webster I. General practitioners' promotion of healthy lifestyles: what patients think. *Aust and NZ J Public Health* 1996; 20 (2): 195-200.
- (145) Wodak A, Drucker E. Re-inventing methadone. *Addiction Research*. 1996; 3: 281-283.
- (146) Dolan K, Wodak A, Hall W, Gaughwin M, Rae F. HIV risk behaviour of IDUs before, during and after imprisonment in New South Wales *Addiction Research* 1996; 4 (2): 151 - 160.
- (147) Wodak A, Crofts N. Reinventing hepatitis C: from interferon deficiency to control. *Aust and NZ J Public Health* 1996; 20: 231-233.
- (148) O'Neill K, Baker A, Cooke M, Collins E, Heather N, Wodak A. Evaluation of a cognitive-behavioural intervention for pregnant injecting drug users at risk of HIV infection. *Addiction* 1996; 91: 1115-1125.
- (149) Wodak A. A stupendous public health achievement. Commentary on "Has the United Kingdom averted an epidemic of HIV - 1 infection among drug injectors? *Addiction* 1996; 91: 1090-1092.
- (150) Wodak A, Dolan K. HIV prevention in the community: injecting drug users. *Med J Aust* 1996; 165: 266-7.
- (151) Rutter S, Dolan K, Wodak A. Rooms for rent: injecting and harm reduction in Sydney. [letter] 1996; *Aust and NZ J Public Health* 21 (1): 105.

- (152) Wodak A. Hepatitis C: Waiting for the Grim Reaper. *Med J Aust.* (Editorial) 1997; 166: 284-285.
- (153) MacDonald M, Wodak AD, Ali R, Crofts N, Cunningham PH, Dolan KA, Kelaher M, Loxley WM, van Beek I, Kaldor JM. HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Med J Aust* 1997; 166 (5): 237-240.
- (154) Wodak A, Lurie P. A tale of two countries: Attempts to control HIV among injecting drug users in Australia and the United States. *Journal of Drug Issues.* 1997; 27 (1):117-134.
- (155) Wodak A. Needle exchange: just do it! *AIDS Targeted Information.* 1997; 11 (5): R 47-R 49.
- (156) Wodak A. Public health and politics - the demise of the ACT heroin trial. (Editorial) *Med J Aust* 1997; 167: 348-349.
- (157) Wodak A. Injecting nation: achieving control of hepatitis C in Australia. *Drug and Alcohol Review.* 1997; 16: 275-284.
- (158) Quinn D, Wodak A, Day R. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. *Clinical Pharmacokinetics.* 1997; 33 (5): 344-400.
- (159) Hall W, Mattick RP, Saunders JB, Wodak A. Rapid opioid detoxification treatment. (Editorial). *Drug and Alcohol Review.* 1997; 16: 325-327.
- (160) Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. *Journal of Epidemiology and Community Health.* 1997; 51 (6): 692-697.
- (161) Crofts N, Deany P, Wodak AD. Challenge and response: HIV in Asia and the Pacific. *Med J Aust* 1997; 166: 509-510.
- (162) Richmond RL, G-Novak K, Kehoe L, Calfas G, Mendelsohn CP, Wodak A. Effect of training on general practitioners' use of a brief intervention for excessive drinkers. *Aust NZ J Pub Health* 1998; 22: 206-209.
- (163) Wodak A. Health, HIV infection, human rights and injecting drug use. *Health and Human Rights.* 1998; 2 (4): 24-41.
- (164) Bramley-Moore SR, Wodak AD, Day RO, Lachlan RL. Patterns of analgesic prescribing in patients with chronic non-malignant pain in NSW. *The Australian Journal of Hospital Pharmacy* 1998; 28 (2): 83-88.
- (165) Wodak A. Heroin prescribing: nothing to fear but fear itself? (Editorial) *Med J Aust* 1998; 168: 590-591.
- (166) Dolan K, Wodak A, Hall W. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. *Drug Alcohol Review.* 1998; 17: 153-158.

- (167) Strathdee S, van Ameijden E, Mesquita F, Wodak A, Rana S, Vlahov D. Can epidemics of HIV among injecting drug users be prevented? *AIDS*. 1998; 12: S71-S79.
- (168) Dolan K, Wodak A, Hall W, Kaplan E. A mathematical model of HIV transmission in NSW prisons. *Drug and Alcohol Dependence*. 1998; 50: 197-202.
- (169) Wodak A, Strathdee S, Friedman SR, Byrne J. The global response to the threat of HIV infection among and from injecting drug users. *AIDS Targeted Information*. 1998; 12 (6): R 41-R 44.
- (170) Richmond R, Wodak A, Bourne S, Heather N. Screening for Unhealthy Lifestyle Factors in the Workplace. *Aust NZ J Pub Health* 1998; 22 (3): 324-331.
- (171) Wodak A. Aspects of care for the hepatitis C positive patient. *Aust Family Physician*. 1998; 27 (9): 787-790.
- (172) Richmond R, Wodak A, Kehoe L, Heather N. How healthy are the police? A survey of lifestyle factors. *Addiction*. 1998; 93 (11): 1729-1737.
- (173) Richmond R, Wodak A. Where should alcohol and tobacco interventions be provided? *Aust NZ J Pub Health*. 1998; 22 (7): 745-746
- (174) MacDonald M, Sullivan P, Locke A, Wodak A, Kaldor J. HIV and HCV prevalence among trawler crew. *Aust and NZ J Public Health* 1998; 22:829-831.
- (175) Drucker E, Lurie P, Wodak A, Alcabes P. (Eds W Darrow and A Oakley). Measuring harm reduction: The Effects of Needle Exchange Programs and Methadone Maintenance Treatment on the Ecology of HIV. *AIDS* 1998; Supplement 12, July.
- (176) Dolan K., Wodak A, Hall W. A bleach program for inmates in NSW: an HIV prevention strategy. *Aust and NZ J Public Health* 1998; 22 (7): 838-840.
- (177) MacDonald M, Wodak A. Preventing transmission of hepatitis C. *Australian Family Physician*. 1998; 28 (special issue): 14-18.
- (178) Hall W, Wodak A. Is naltrexone a cure for heroin dependence? *Med J Aust* 1999; 171: 9-10.
- (179) Wodak A, Baume P. The New South Wales Drug Summit. *Med J Aust* 1999; 171: 12-13.
- (180) Dolan K, Wodak A. HIV transmission in a prison system in an Australian state. *Med J Aust* 1999; 171: 14-17.
- (181) Wodak A. Responding to the epidemic of drug overdose deaths. *Current Therapeutics* 1999; 40: 9-11.
- (182) Dolan K, Wodak A, Hall W. HIV risk behaviour and prevention in prison: a bleach programme for inmates in NSW. *Drug and Alcohol Review* 1999; 18(2): 139-143.

- (183) Wodak A. What is this thing called harm reduction? *International Journal of Drug Policy*. 1999; 10:169-171.
- (184) Richmond R, Kehoe L, Hailstone S, Wodak A, Uebel-Yan M. Quantitative and Qualitative evaluations of brief interventions to change excessive drinking, smoking and stress in the police force. *Addiction*. 1999; 94 (10): 1509-1521.
- (185) Wodak A. Summary and Conclusions. (Special Issue 'Regulating Cannabis: Comparative Perspectives'). *International Journal of Drug Policy* 1999; 10 (4): 277-280.
- (186) Shearer J, Wodak A, Mattick RP, van Beek I, Lewis J, Hall W, Dolan K. A randomised controlled trial of monitoring controlled prescribing of dexamphetamine. NDARC Technical Report 75. 1999.
- (187) MacDonald MA, Wodak AD, Dolan KA, van Beek I, Cunningham PH, Kaldor JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia 1995-7. *Med J Aust* 2000; 172:57-61.
- (188) O'Sullivan AJ, Kennedy M C, McCorby S, Casey JH, Day RO, Corrigan B, Wodak A. Anabolic-androgenic steroids: medical assessment of present, past and potential users. *Med J Aust* 2000; 173: 323 – 327.
- (189) Wodak A. Drug treatment for opioid dependence. *Australian Prescriber* 2001; 24 (1): 4-6.
- (190) Wodak A. Developing a medical response to psychostimulants. *Addiction Research*. 2001; 9 (2): 93-96.
- (191) Wodak A, Hall W. 2001) Buprenorphine: better late than never. *Med J Aust* 2001; 175: 349-350.
- (192) Baker A, Heather N, Wodak A, Lewin T. Heroin use and HIV risk-taking behaviour among women injecting drug users. *Drug and Alcohol Review* 2001; 20 (2): 205-211.
- (193) Shearer J, Wodak A, Mattick RP, van Beek I, Lewis J, Hall W, Dolan K. Pilot randomized controlled trial of dexamphetamine substitution for amphetamine dependence. *Addiction* 2001; 96 (9) 1289-1296.
- (194) Wodak A, Reinerman C, Cohen P. Controlling cannabis: the current cure is worse than the disease. *Brit Med J* 2002; 324: 105-108.
- (195) Wodak A. Methadone and heroin prescription. *Methadone and heroin prescription: babies and bath water*. *Substance Use and Misuse* 2002; 37 (4): 523-530.
- (196) Shearer J, Sherman J, Wodak A, van Beek I. Substitution therapy for amphetamine users, *Harm Reduction Digest* 17, *Drug and Alcohol Review* 2002; 21 (2), 179-185.
- (197) Graham R, Wodak A, Whelan G. New pharmacotherapies for alcohol dependence. *Med J Aust* 2002; 177 (2): 103-107.

- (198) Dolan K, Rutter S, Wodak A. Prison based syringe exchange programs: A review of international research and development. *Addiction* 2003; 98, 153-158.
- (199) Shearer, J., Wodak, A., van Beek, I., Mattick, R., & Lewis, J. Pilot randomized double blind placebo controlled study of dexamphetamine for cocaine dependence. *Addiction* 2003; 98: 1137-1141.
- (200) Wodak A. The international drug treaties: 'paper tigers' or dangerous behemoths? *International Journal of Drug Policy*. 2003; 14: 221-223.
- (201) Dolan KA, Shearer J, Macdonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. *Drug and Alcohol Dependence*. 2003 Volume 72, Issue 1: 59-65.
- (202) Law M, Dore G, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. *International Journal of Epidemiology*. 2003. 32: 717-724.
- (203) Wodak A, Symonds A, Richmond R. The role of civil disobedience in drug policy reform: how an illegal 'safer injecting room' led to a sanctioned 'medically supervised injection centre'. *Journal of Drug Issues*. 2003. 33 (3); 609-624.
- (204) Wilhelm K, Richmond R, Wodak A. Clinical aspects of nicotine dependence and depression. *Medicine Today*. 2004; 5 (1): 40-47.
- (205) Wodak A, Lynch P, Crofts N. Is lawful discrimination against drug users acceptable? *Med J Aust* 2004; 180 (8): 1-3.
- (206) Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, Schechter MT, Tyndall MW. Rationale for evaluating North America's first medically supervised safer-injecting facility. *Lancet Infect Dis*. 2004; 4(5):301-6.
- (207) Wodak A, Sarkar S, Mesquita F. The globalisation of drug injecting. *Addiction*. 2004; 99: 799-801
- (208) Lynch P, Wodak A. Partnering for Public Health and Social Justice. *Alternative Law Journal*. 2004; 29: 168-173.
- (209) Ritter AJ, Wodak AD, Crofts JN. Reducing drug-related harm: Australia leads the way. *Med J Aust* 2004; 181 (5): 242-243.
- (210) Wodak A, Ali R, Farrell M. Editorial. HIV in injecting drug users in Asian countries. *British Medical Journal* 2004; 329: 697-698.
- (211) Wodak A, Cooney A. Should cannabis be taxed and regulated? *Drug and Alcohol Review* 2004; 23:2; 139-141.
- (212) Kerr T, Wodak A, Elliot R, Montaner JS, Wood E. Opioid substitution therapy and HIV/AIDS treatment and prevention. *Lancet*. 2004; 364; 1918-1919.

- (213) Dolan K, Clement N, Rouen D, Rees V, Shearer J, Wodak A. Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs? *Drug and Alcohol Review* 2004; 23, 281 – 286.
- (214) Dolan K, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction* 2005; 100: 820-828.
- (215) Kimber J, Dolan K, & Wodak A. Survey of drug consumption rooms: service delivery and perceived public health and amenity impact. *Drug and Alcohol Review* 2005; 24: 21 – 24.
- (216) Wodak A. The current status of heroin prescription treatment for heroin dependence. *Expert Opinion on Drug Safety*. 2005; 4 (5): 815-819.
- (217) Wodak A. Is the Howard Government tough on drugs? *Social Research Briefs*. National Centre for HIV Social Research. Number 7, September 2005.
- (218) Wodak AD. The US war on harm reduction: fixing policy on intelligence and facts. *Harm Reduction Journal* 2005, 2:14 (15 Sep 2005) <http://www.harmreductionjournal.com/content/2/1/14>
- (219) Baker A, Ivers RG, Bowman J, Butler T, Kay-Lambkin FJ, Wye P, Walsh RA, Pulver LJ, Richmond R, Belcher J, Wilhelm K, Wodak A. Where there's smoke, there's fire: High prevalence of smoking among some sub-populations and recommendations for intervention. *Drug and Alcohol Review*. 2006; 25; 85 – 96.

## 15 SUBMITTED FOR PUBLICATION:

- (1) Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: economic evaluation of prison methadone. *Drug and Alcohol Dependence*. [in press]
- (2) Campbell T, Oei J, Feller JM, Wodak AD, Lui K. The Impact of the Australian Heroin Shortage on the Care of Drug-dependent Pregnant Women and their Infants. [submitted]
- (3) Cooney A, Wodak A. Effectiveness of sterile needle and syringe programmes. [*International Journal of Drug Policy*. in press]
- (4) Hla-Hla Thein, Jialun Zhou, Alex D Wodak, Kate A Dolan, Ingrid van Beek, Philip H Cunningham, John M Kaldor, Lisa Maher, Gregory J Dore, Margaret MacDonald. Hepatitis C prevalence and risk behaviours among young injecting drug users in Australia. [in preparation]
- (5) Butler T, Belcher JM, Richmond RL, Wodak AD, Wilhelm KA. High smoking rates in NSW prisons: Area of concern and opportunities. [in preparation]
- (6) Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. *Substance Use and Misuse*. [in press]

- (7) Fawcett J, Shakeshaft A, Mattick R, Richmond R, Wodak A, Harris M. Patient-driven computers in routine primary care: rationale and pilot data. [in preparation]
- (8) Shearer J, Gilmour S, White B, Wodak A, Dolan K. Detection of drug use among prisoners: self report versus hair testing. [submitted]
- (9) Kramer D, Wodak A. The International Drug Regulatory System and the Use of Buprenorphine for Substitution Treatment of Opioid Dependence. [submitted Drug and Alcohol Review]
- (10) Richmond RL, Butler T, Belcher JM, Wodak AD, Wilhelm KA, Baxter E. Reducing smoking among prisoners: a feasibility study [in preparation]
- (11) Wodak A. All drug politics is local. International Journal of Drug Policy. [in press]
- (12) Wodak A. The US War On Harm Reduction: fixing policy on intelligence and facts. Harm Reduction Journal. [in press]
- (13) Wodak A. Harm Minimisation – the current state of play in Australia. Development Bulletin. [submitted]
- (14) Dolan K, Shearer J, Wodak AD. Comparison of naltrexone, methadone, buprenorphine and drug free counseling in imprisoned male heroin users. [submitted]
- (15) Baker A, Ivers RG, Bowman J, Butler T, Kay-Lambkin FJ, Wye P, Walsh RA, Pulver LJ, Richmond R, Belcher J, Wilhelm K, Wodak A. Where there's smoke, there's fire: High prevalence of smoking among some sub-populations and recommendations for intervention. [submitted]
- (16) Shakeshaft A, Fawcett J, Mattick RP, Richmond R, Wodak A, Harris MF, Doran CM. Patient driven computers in primary care: their use and feasibility. Health Education [in press - scheduled publication date: September 2006]

## 16 BOOKS, CHAPTERS:

- (1) Richardson PJ, Wodak AD. Alcohol-induced Heart Muscle Disease. In: "Specific Heart Muscle Disease" (eds) Symons C, Evans T, Mitchell AG, and Harvey WP. pp 99-122. Wright P.S.G. London (1983)
- (2) Francis M, Richmond RL, Wodak A, Webster IW. "Controlling Your Drinking". Sydney: School of Community Medicine, University of New South Wales (1987).
- (3) Contributor: "What do I do in an Emergency?" Reader's Digest. Sydney Auckland (1987).
- (4) Wodak AD. Emergency Presentations of Alcohol and Drugs. In: Emergency Medicine: The Principles of Practice. (Ed. G.W.O. Fulde). pp 301-311. Williams and Wilkins. Sydney. (First Edition: 1988, Second Edition: xx pp xx; Third Edition: 1997 pp xx).

- (5) Heather N, Richmond R, Webster I, Wodak A with Hardie M., Polkinghorne H. "A guide to healthier drinking". Sydney: School of Community Medicine and, National Drug and Alcohol Research Centre, University of New South Wales, (1989).
- (6) Gossop M, Grant M, and Wodak A. (Eds). The uses of methadone in the treatment and management of opioid dependence. WHO, Division of Mental Health. Geneva (1989).
- (7) The Effectiveness of Treatment for Drug and Alcohol Problems : An Overview. Edited by: Nick Heather and Jennifer Tebbutt. Written by: N Heather, R Batey, J B Saunders, A D Wodak. National Campaign Against Drug Abuse. Monograph series No. 11. (1989).
- (8) Wodak A, Gold J. AIDS and Intravenous Drug Use. In: AIDS and other Sexually Transmitted Diseases. (Eds. R. Richmond and D. Wakefield) W.B. Saunders Balliere Tindall. Sydney. pp 149-157. (1989)
- (9) Wodak A. AIDS and injecting drug use in Australia: A case study in policy development and implementation. In: AIDS and Drugs Misuse: The Challenge for Policy and Practice in the 1990s. (Eds. Strang J., Stimson) G.V. Routledge. London. (1990).
- (10) Wodak A. Alcoholism. In: Conn's Current Therapy. Ed. R.E. Rakel, M.D. Section 16: Psychiatric Disorders. 999-1004. W.B. Saunders Company. (1990).
- (11) Wodak A. Alcoholism. In: Conn's Current Therapy. Ed. R.E. Rakel, M.D. Section 16: Psychiatric Disorders. 1035-1040. W.B. Saunders Company. (1991).
- (12) Wodak A. Beyond the Prohibition of Heroin: the development of a controlled availability policy. In: "Australia: Strategies for Renewal. The Unwinnable War Against Drugs: the politics of decriminalisation". (Ed. J. Mathews). Australian Fabian Society, Socialist Forum. Pluto Press. pp 53-71. (1991).
- (13) Wodak A. 'To Shun the Heaven that leads man to this hell': AIDS and Drug injection. Chapter - AIDS and Drug Use. Handbook in Addiction Behaviour. Routledge Publishers. (Ed. I. Glass). pp 126-133. (1991).
- (14) Australian National AIDS and Injecting Drug Users Study. First Report of the Australian National AIDS and Injecting Drug Users Study, 1989 Data Collection. "Neither a Borrower nor a Lender Be:". Sydney. (1991).
- (15) Wodak AD, Shaw JM, Gaughwin MD, Ross MW, Miller ME, Gold J. Behind bars: HIV risk-taking behaviour of Sydney male drug injectors while in prison. In: HIV/AIDS and Prisons. (Eds Norberry J, Gaughwin M, and Gerrull SA). Canberra: Australian Institute of Criminology Conference Proceedings 4: 239-44. (1991).
- (16) Gaughwin MD, Douglas RM, Wodak AD. Behind bars - risk behaviours for HIV transmission in prisons: a review. In: HIV/AIDS and Prisons. (Eds Norberry J, Gaughwin M, and Gerrull SA). Canberra: Australian Institute of Criminology Conference Proceedings 4: 89-107. (1991).



- (17) Baker A, Heather N, Wodak A. The application of self-control strategies to reducing HIV risk-taking behaviour in intravenous drug users. N. Heather, W.R. Miller & J. Greeley (Eds.), *Self-control and the addictive behaviours*. Maxwell Macmillan Publishing Australia, Sydney. 357-367. (1991).
- (18) Wodak A, Richmond R, Webster I, Scanlon K, Solomon M. ALCOHOLSCREEN - Detection, Assessment and Minimal Intervention for Problem Drinkers in General Practice. *Screening for Drug Abuse-A Community Challenge* (eds. James Bell & Lindsay Wyndham) The Clinical Biochemist. Monograph. Proceedings of a Conjoint Conference organised by the Australian Association of Clinical Biochemists and the Australian Medical And Professional Society on Alcohol and Drugs. pp 22-26. (1991).
- (19) Wodak A. To take up arms against a sea of drugs. HIV infection and AIDS. Present status and future prospects for prevention, treatment and cure. Proceedings of the 1991 Annual General Meeting of the Australian Academy of Science. The Australian Academy of Science. Canberra. pp 61-70. (1991).
- (20) Wodak AD. Emergency Presentations of Alcohol and Drugs. In: *Emergency Medicine: The Principles of Practice*. (Ed. G.W.O. Fulde). Second Edition. Williams and Wilkins. Sydney. pp 359-372. (1992).
- (21) Ross MW, Wodak A, Miller ME, Gold J. Attitudes towards termination of pregnancy and associated risk behaviours in drug-injecting women. Melica F. (ed ) in *AIDS and Human Reproduction: Proceedings of the First International Symposium*. AIDS and Reproduction. Genoa. 1990. Basel, Karger. 55-60. (1992).
- (22) Wodak A. Beyond the prohibition of heroin: The development of a controlled availability policy in Australia. In O'Hare P.A., Newcombe R., Mathews A., Buning E. C., Drucker E. (eds) *The Reduction of Drug -Related Harm*. Routledge, London pp 49-61. (1992).
- (23) Wodak A, Dwyer R, Ross MW, Drury MJ, Gold J, Miller ME. Life at the Epicentre: sex and drug using behaviour in Sydney. ANAIDUS. Sydney (1992).
- (24) Wodak A. Coping with substance abuse: a many sided task. World Health Forum. World Health Organisation. (1992); 13 : 101-111.
- (25) Heather N, Wodak A, Nadelmann E, O' Hare P. (eds) *Psychoactive Drugs and Harm-reduction: From Faith to Science*. Whurr Publishers, London (1993).
- (26) Heather N, Wodak A, Nadelmann E, O' Hare P. Preface to Heather N, Wodak A, Nadelmann E, O' Hare P. (eds) *Psychoactive Drugs and Harm-reduction: From Faith to Science*. Whurr Publishers, London (1993).
- (27) Wodak A, Fisher R, Crofts N. An evolving public health crisis: HIV infection among injecting drug user in developing countries. In "Psychoactive Drugs and Harm-reduction: From Faith to Science." eds N. Heather, A. Wodak, E. Nadelmann and P. A. O' Hare. Whurr Publishers, London. pp 278-292. (1993)

- (28) Wodak A. Reducing alcohol-related harm through treatment: treatment effectiveness research and the problem of attribution. *Tijdschrift voor alcohol, drugs en andere psychotrope stoffen*. (eds) HFL Garretsen, P Blanken, LAM Van de Goor. Swets & Zeitlinger. Lisse. 244-250. (1994)
- (29) Wodak A. Needle exchange and bleach distribution programmes: the Australian experience. *Proceedings: Workshop on Needle exchange and bleach distribution programs. Panel on Needle exchange and bleach distribution programs. Commission on Behavioral and Social Sciences and Education, National Research Council and Institute of Medicine. National Academy Press. Washington DC. pp 91-108. (1994)*
- (30) Wodak A, van Beek I. AIDS and injecting drug users. *The AIDS Manual. A comprehensive reference on the Human Immunodeficiency Virus. (HIV) ed. J. Gold, R. Penny, M. Ross, S. Morey, G. Stewart, B. Donovan, S. Berenger. Third Edition. MacLennan and Petty. pp 165-169. (1994)*
- (31) Wodak A, Des Jarlais D. Estratégias para a prevenção da infecção pelo HIV entre usuários de drogas e destes para os seus parceiros. in: (eds) Fábio Mesquita, Francio Inácio Bastos. *Drogas e AIDS. Estratégias de Redução de Danos. Editora Hucites. São Paulo. pp 115-132. (1994)*
- (32) Wodak A, Fisher R, Crofts N. Uma crise emergente no âmbito da Saúde Pública - a infecção pelo HIV entre usuários de drogas injetáveis nos países em desenvolvimento. in: (eds) Fábio Mesquita, Francio Inácio Bastos. *Drogas e AIDS. Estratégias de Redução de Danos. Editora Hucites. São Paulo. pp 149-168. (1994)*
- (33) Dolan K, Hall W, Wodak A. Bleach availability and Risk Behaviour in Prison in New South Wales. *Technical Report No 22. Sydney: National Drug and Alcohol Research Centre. (1994)*
- (34) Richmond R, Heather N, Wodak A, Kehoe L, Webster I. Controlled evaluation of a general practice-based brief intervention for excessive alcohol consumption: the Alcohol screen Project. *Sydney: National Drug and Alcohol Research Centre. (1994)*
- (35) Richmond R, Heather N, Wodak A, Faux S. *The Drinking Detective: Let's Drink to Your Health. (1994)*
- (36) Wodak A. Harm Reduction in Australia. J. Götz (ed). in *Der drogen-abhängige Patient. Urban und Schwarzenberg. München. Germany, pp 1995, 132-136.*
- (37) Stowe A, Ross MW, Wodak A, Thomas GV, Larson SA. Significant relationships and social supports of injecting drug users and their implications for HIV/AIDS services. in Robert Bor (ed) *The impact of HIV/AIDS on the family and significant relationships. Cassell. ]*
- (38) Wodak A, Owens R. *Drug Prohibition: a call for change. UNSW Press. Sydney. (1995)*
- (39) Ball A, Des Jarlais D, Donoghoe MC, Friedman SR, Goldberg D, Hunter GM, Stimson SV, Wodak A. *Multi-centre study on drug injecting and the risk of HIV infection: a report on behalf of the international collaborative group for the World Health Organisation Programme on Substance Abuse. World Health Organisation. Geneva. (1995)*

- (40) Wodak A. (1995) Stopping drugs and staying off them. in *Perspectives on Addiction: Making sense of the issues*. pp 142-147. C. Wilkinson, B. Saunders. (eds). William Montgomery Pty Ltd. Perth.
- (41) Drew LRH, Wodak A. Drug Abuse. *The Australian Encyclopaedia*. Australian Geographic Pty. Ltd. Terrey Hills. (1996) pp 1107-1109.
- (42) Dolan K, Shearer J, Hall W, Wodak A. Bleach easier to obtain but inmates still at risk of infection in New South Wales prisons. Technical Report No 34. Sydney: National Drug and Alcohol Research Centre. (1996)
- (43) Rutter S, Dolan K, Wodak A, Hall W, Maher L, Dixon D. Is syringe exchange feasible in a prison setting? An exploratory study of the issues. Technical Report No. 25. National Drug and Alcohol Research Centre. (1996)
- (44) Rutter S, Dolan K, Wodak A. Sex, drugs and viruses in Sin City. Sydney 1994. *The Second Report of the Australian Study of HIV and Injecting Drug Use*. NDARC. (1996)
- (45) Janusic T, Mant A, Richmond R, Bell J, Wodak A, Webster I. Teaching and evaluating brief intervention skills for alcohol management in the clinical school. [in preparation]
- (46) Baker A, Heather N, Stallard A, O'Neill K, Wodak A. *A Manual of Cognitive Behavioural Techniques Aimed at Reducing HIV Risk Taking Behaviour in Injecting Drug Users*. National Drug and Alcohol Research Centre Monograph Number 28. 1996. Sydney.
- (47) Donoghue M C, Wodak A. Health and Social consequences of injecting drug use. in eds Stimson GV, Des Jarlais DC, Ball A. *Drug Injecting and HIV Infection: Global dimensions and Social responses*. Taylor and Francis. London. 1998 pp 42-57.
- (48) Dolan K, Hall W, Wodak A. The provision of methadone within prison settings. in Ward J, Hall W, Mattick R. (eds) *Methadone maintenance and other opioid replacement therapies*. Amsterdam Harwood Academic Publishers. 1998.
- (49) Wodak A. "Harm Reduction as an approach to treatment". in *"Principles of Addiction Medicine, Second Edition"*. American Society of Addiction Medicine. eds Allan W. Graham, Terry K. Schultz. 1998. pp 395-404.
- (50) Wodak A. Drug Regulation in the Post-Prohibition Era. in *"Twenty-Twenty Vision: Mental Health in the 21 st Century"*. 1996 Geigy Psychiatric Symposium. Ed Vaughan J. Carr. pp 52-62. Norvatis Australia. North Ryde. 1997.
- (51) Wodak A. Redução de Danos e Programas de Troca de Seringas. in *"Troca de Seringas: Drogas e AIDS. Ciência, Debate e Saúde Pública"*. eds: Francisco Inácio Bastos, Fábio Mesquita. Brasil Ministério de Saúde. Brasilia. 1998. 55-72.

- (52) Nadelmann E, Cohen P, Locher U, Stimson G, Wodak A, Drucker. El enfoque de reducción de daños para el control de drogas: progreso internacional. in: El rompecabezas de las drogas ilegales en Estados Unidos (Una visión eléctrica). Compiladores: Alexandra Guáqueta, Francisco E. Thoumi. Ediciones Uniandes. Bogotá, Colombia. 1997. pp 87-136.
- (53) Wodak A. Medical complications of drug taking. (Ed) R. Robertson. Management of drug users in the community. Arnold. London. 1998. pp 138-152.
- (54) Wodak A, Hoy J. HIV infection and injecting drug use. In Suzanne Crowe, Jennifer Hoy, John Mills. (Ed) Management of the HIV infected patient. (in press). 2002. Martin Dunitz. London. Second Edition. pp 575-584.
- (55) Wodak A. Developing more effective responses. Eds G. Stokes, P. Chalk, K. Gillen. Illicit Drugs and Australian Democracy. Carlton South. Melbourne University Press. 2000 pp 183-200.
- (56) Wodak A. Developing more effective responses to illicit drugs in Australia. In: Heroin crisis. Melbourne: Bookman. 2000: 197-210.
- (57) Crofts N, Wodak A. Gaining control of the hepatitis C virus epidemic in Australia. in Hepatitis C. An Australian Perspective. Nick Crofts, Greg Dore, Stephen Locarnini. (eds) IP Communications. Melbourne. 2001. pp 342-356.
- (58) Wodak A, Moore T. Modernising Australia's Drug Policy. UNSW Press. Sydney. 2002.
- (59) Kimber J, Dolan K, & Wodak A (2001). International Survey of Supervised Injecting Centres (1999-2000). Technical Report No. 126, National Drug and Alcohol Research Centre. University of New South Wales, Sydney
- (60) Gary Hulse, MR Basso, A. Wodak. 'The Injecting Drug User' by. Management of Alcohol and Other Drug Problems. (eds) Gary Hulse, Jason White and Gavin Cape. Oxford University Press. Melbourne. 2003.
- (61) Wodak A. Australia's response to HIV among injecting drug users: the band is still playing. HIV and hepatitis C: policy, discrimination, legal and ethical issue. ed Marina Carman. Australian Society of HIV Medicine. 2005. Sydney. pp 33-42.
- (62) Dolan K, Shearer J, White B, Wodak A. A randomised controlled trial of methadone maintenance treatment in NSW prisons. NDARC Technical Report No. 155 2002.
- (63) Drucker E, Nadelmann E, Newman RG, Wodak A. Mc Neely J, Malinowska -Semprucht K, Marsh D, Schechter M, Brands B, Oscapella E. Harm Reduction: Pragmatic Drug Policies for Public Health and Safety. in JH Lowinson, P Ruiz, RB Milkman, JG Langrod. et al, Eds. Substance Abuse: A Comprehensive Textbook. 4th Edition. 2005. Philadelphia. 1299-1249.
- (64) Black E, Wodak A, Dolan K. Supply, demand and harm reduction strategies in Australian prisons. Implementation, cost and evaluation. Australian National Council on Drugs (ANCD). Research paper number 9. Australian National Council on Drugs, Canberra, 2004.

- (65) Wodak A. Drugs, Crime and Crime Reduction. In 'Australian Crime and Criminal Justice. 2005. (eds) Paul Wilson, Duncan Chappell. Lexis Nexis Butterworths. Chatswood. pp 197-219.
- (66) Wodak A, Cooney A. Evidence For Action Technical Papers. Effectiveness of Sterile Needle And Syringe Programming in Reducing HIV/AIDS among Injecting Drug Users. World Health Organisation, Geneva, 2005. [http://www.who.int/hiv/pub/prev\\_care/en/effectivenesssterileneedle.pdf](http://www.who.int/hiv/pub/prev_care/en/effectivenesssterileneedle.pdf)
- (67) Wodak A. Health, HIV infection, human rights and injecting drug use. in 'War on Drugs, HIV/AIDS and Human Rights.' eds Kasia Malinowska-Sempruch, Sarah Gallagher. International Debate Education Association. New York. 2004.
- (68) Kehoe, P. & Wodak A. (2004). Patient satisfaction in a NSW public opioid pharmacotherapy clinic: measurement and responses. Technical Report 194. National Drug and Alcohol Research Centre.
- (69) Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience.

## 17 OTHER PUBLICATIONS:

### Book Reviews

- (1) Preventing HIV Transmission. The role of Sterile Needles and Bleach. Jacques Normand, David Vlahov and Lincoln Moses (eds). National Academy Press. Washington DC. 1995. *Addiction*. 1996. 91: 1551-1557.
- (2) In Retrospect. The Tragedy and Lessons of Vietnam. Robert S. McNamara. Times Books. New York. 1995. *International Journal of Drug Policy*. 1997. 8(3): 161-162.
- (3) Alcohol in Health and Disease. Dharam P Agarwal, Helmut K Seitz. Eds. New York. Marcel Dekker. 2001. *Addiction* 2002. 97: 240.

## 18 RESEARCH GRANTS:

A multi-component intervention for smoking cessation among Australian prison inmates. Richmond R, Butler T, Wilhelm K, Wodak A. 2004. \$ 301,500 year 1, \$163,250 year 2, \$81,500 year 3. Total: \$ 546,250. NHMRC

Comparing the role of takeaways in methadone maintenance treatment in NSW and Victoria. Van de Ven P, Wodak A, Treloar C, Fraser S. NHMRC 300443 3 years \$285,375 2004.

A Randomised Controlled Trial of naltrexone, methadone and counselling in NSW prisons. Investigators: Kate Dolan Margaret MacDonald and Alex Wodak, NSW Corrections Health Service \$259,176.36. 2001-2003.

A literature review of prison based syringe exchange programs. ACT Corrective Services, 2000. \$18,807. Grant holders: Kate Dolan and Alex Wodak.

Follow up of the NSW prison methadone study. NHMRC # ID NIDS 055 2000 \$40,416, 2001 \$40,415, 2002 \$40,415. Investigators: Kate Dolan, Alex Wodak John Kaldor and Wayne Hall.

Cost benefit study of the NSW prison methadone program Funded by NHMRC # NIDS 056 2001 \$61,157. Investigators: Kate Dolan, Rosalie Viney and Alex Wodak.

Feasibility study of non-injecting routes of administration among intravenous drug users. NH&MRC # 98/3615 1999/2000: \$60,000. Grant Holders: Alex Wodak, Kate Dolan, Lisa Maher and Vaughan Rees.

Urinary amphetamine isomer monitoring of controlled prescribing of amphetamines. RIDAC. Grant holders: Richard Mattick, Wayne Hall Alex Wodak, Kate Dolan and James Shearer \$70,000.

Randomised Control Trial of the NSW Prison Methadone Program. \$240,000 Research Into Drug Abuse Committee. Grant holders: Alex Wodak, Wayne Hall, Richard Mattick and Kate Dolan.

Contact tracing among ex-prisoners. NSW Department of Health. \$85,000. Grant holders: Grant Holders: Kate Dolan, Alex Wodak, Dominic Dwyer and Wayne Hall.

An analysis of trends over time in social and behavioural factors related to the transmission of HIV among IDUs and prison inmates. Commonwealth Department of Human Services and Health. \$32,044. Grant holders: Grant Holders: Nick Crofts, Alex Wodak, Wendy Loxley, Julie Webb-Pullman, Kate Dolan and Susan Carruthers. 1995.

Monitoring risk behaviour and seroprevalence of blood borne viruses at needle exchanges. Commonwealth AIDS Research Grant 1995 \$ 87, 460. Grant holders: Alex Wodak, Margaret MacDonald Kate Dolan and Margaret Kellaheer.

Feasibility research into the introduction or exchange of injecting equipment in prison. Australian Research Council Amount \$4,539. Grant holders: Kate Dolan, David Dixon, Alex Wodak, Lisa Maher and Wayne Hall, 1995

An evaluation of a programme of bleach distribution to prisoners in Australia. Funded by CARG \$64,280. Grant holders: Kate Dolan, Wayne Hall and Alex Wodak. 1994 - 1995.

An evaluation of a programme of bleach distribution to prisoners in NSW. Funded by NSW AIDS and Infectious Diseases Branch. Amount: \$8,000 Grant holders: Kate Dolan, Alex Wodak and Wayne Hall. May 1993 to March Dec 1994.

Australian Study of HIV and Injecting Drug Use (ASHIDU). Funded by Commonwealth AIDS Research Grant and the Drugs of Dependence Branch. Amount \$221,575 Grant holders: Alex Wodak, Wendy Loxley, Nick Crofts, Kate Dolan, Matt Gaughwin and Elizabeth Dax. February 1994 to January 1995.

Monitoring HIV risk behaviour and infection among ex-prisoners. Funded by Commonwealth AIDS Research Grant. Amount: \$51,564. Grants holders: Alex Wodak, Matt Gaughwin, Wayne Hall and Kate Dolan

Wodak, A., Van Beek, I., Bell., J. 2003 \$151840 2004 \$151840

Wodak A., Van Beek I., Ali, R, Lintzeris N. 2003 \$204,240 2004 \$204,240

A collaborative study of AIDS and IV drug users

Wodak AD, Gold J, Steur M, Mugford S, Berg R.

1988 \$68,000

1989 \$ 218,000

1990 \$ 208,546

Commonwealth AIDS Research Grants

National Injecting Drug and AIDS Study

Wodak A, Monheit B, Hawks D, Loxley W, Buzolic A.

1991 \$254,270

Commonwealth AIDS Research Grants

Evaluation of a cognitive behavioural interventions among IVDUs at risk for HIV.

Wodak AD, Heather BB.

1989: \$44 711

1990: \$46, 097

Commonwealth AIDS Research Grants

1989: \$36 051

1990: \$41 251

NSW Drug and Alcohol Directorate

Evaluation of a cognitive behavioural intervention for IVDUs not in treatment.

Wodak AD, Heather BB, Baker A.

1991: \$65 677

1992: \$71, 931

1993: \$0

Commonwealth AIDS Research Grants

A Relapse Prevention Programme for Pregnant IDUs at Risk of HIV Infection.

Wodak AD, Collins E, Heather BB, Baker A.

1992: \$102,693

1993: \$85,461.88

Commonwealth AIDS Research Grants

Indices of free radical activity in acute and chronic alcohol exposure.

Hicks M, Day RO, Gebicki JM, Wodak AD.

1991: \$25 860.68

1992: \$21 091.33

1993: \$21 091.33

National Health and Medical Research Council  
 Early and minimal intervention with problem drinkers in general practice.  
 Webster IW, Richmond R, Wodak AD.  
 1991: \$57 590  
 1992: \$59 436  
 1993: \$28 435  
 National Health and Medical Research Council

Monitoring risk behaviour and HIV infection among ex-prisoners  
 Wodak A, Gaughwin M.  
 1993: \$ 38,814.27  
 Commonwealth AIDS Research Grant

An evaluation of a programme of bleach distribution to prisoners in Australia  
 Hall W, Wodak A.  
 1994: \$ 59,565  
 Commonwealth AIDS Research Grant

An evaluation of a programme of bleach distribution to prisoners in Australia  
 Wodak A, Hall W, Dolan K.  
 1994: \$ 8,000  
 NSW AIDS Bureau

Reduction in Alcohol-Related Violence in Eastern Sydney  
 Lee I, Ireland S, Wodak A.  
 1993: \$47,491  
 1994: \$70,517  
 (Total \$118,008)

National Drug Crime Prevention Grant Fund  
 Lee I, Wodak A.  
 Preparation of a manual 1994: \$ 22,900.  
 National Drug Crime Prevention Grant Fund

Validation of a risk-taking behaviour scale for injecting drug users  
 Hall W, Wodak A, Darke S.  
 1990 \$ 32, 576  
 Commonwealth AIDS Research Grant

WHO multi-centre study on IVDUs and HIV infection  
 Wodak AD, Ross MW.  
 1989 \$ 15, 589.00  
 Commonwealth AIDS Research Grant

Australian Study of HIV infection and injecting drug use (ASHIDU)  
 Wodak A, Loxley W, Crofts N, Dolan K, Gaughwin M, Darke S, Dax E, Elford J.  
 Commonwealth AIDS Research Grant 1994 \$ 116,671.67



National HIV/AIDS Evaluation Drugs of Dependence Branch	1994	\$ 57,411
	Total (1994)	\$174,082.67

Commonwealth AIDS Research Grant	1995	\$ 49,328
----------------------------------	------	-----------

National HIV surveillance for injecting drug users  
Chief investigators: Elford J, Kaldor J.  
Other investigator: Wodak A.  
Commonwealth AIDS Research Grant (Number: 946069)

	1994	\$ 54, 288.88
	1995	\$ 54, 288.88

Early intervention skills training for year 6 undergraduates during their clinical attainments. (CADEMS project)  
Mant A, Wodak A, Webster I, Richmond R.  
National Campaign Against Drug Abuse Educational Grant  
\$ 46,842

Development and Evaluation of an early and brief intervention to reduce excessive alcohol consumption in the workplace.  
Richmond R, Heather N, Wodak A.  
Commonwealth Department of Health  
\$ 100.000

An evaluation of a prison methadone program  
Wodak A, Hall W, Dolan K, Mattick R.

	1996	\$ 90,153
	1997	\$ 121,653
	Total	\$ 211,806

Research into Drug Abuse Grant Approved 30.4. 1996		\$ 88,559 for the first year.
---	--	-------------------------------

Co-existence of problem drinking and problem gambling  
Wodak A, Dickerson M, Mattick R.  
Casino Community Benefit Fund Trustees  
[granted 30.12.1996]  
\$ 97,452

Applications for support for 1995

Monitoring risk behaviour and seroprevalence of blood borne viruses at needle exchanges  
Wodak A, Kaldor J, MacDonald M, Dolan K, Kellaheer M.  
Commonwealth AIDS Research Grant

	1995	\$ 87, 460
--	------	------------

Monitoring HIV, HBV and HCV in clients attending selected methadone clinics throughout in Australia  
Kaldor J, Wodak A, MacDonald M.

Epidemiological and virological assessment of an apparent outbreak of HIV infection among prison inmates.

Wodak A, Dolan K, Dwyer D, Hall W.

1995 \$ 62,469

Commonwealth AIDS Research Grant  
[Not funded]

Feasibility Research into the Introduction or exchange of injecting equipment in prison

Dixon D, Wodak A, Dolan K, and Hall W.

1995 \$ 4,539.00

ARC Small Grants Scheme

Applications for support for 1996

An evaluation of a prison methadone program

Wodak A, Hall W, Dolan K, Mattick R.

1996 \$ 68,470

1997 \$ 96,970

Total \$ 165,440

National Health and Medical Research Council  
Department of health and Family Services

1998 \$ 26,950

Urinary amphetamine isomer monitoring of controlled prescribing of amphetamines

Wodak A, Mattick R, van Beek I, Lewis J, Hall W.

1996 \$ 68,792

Research Into Drug Abuse Grants (RIDAP)

A comparative study of buprenorphine and methadone in the treatment of opioid dependence

Mattick R, Oliphant D and Ali R, Hall W, Reynolds A, White J, Wodak A.

National Drug and Alcohol Research Centre \$ 68, 157

Reckitt and Colman \$120, 225

Department of Human Services and Health \$ 75, 595

NSW Department of Health \$ 89, 373

Total \$ 353, 350

Needlestick Risk Assessment in Prisons study: analysis of syringes found in NSW correctional centres.

Dolan K, Wodak A, Hall W.

Applications for support for 1999

Dexamphetamine prescribing as substitution therapy for amphetamine dependence.

Wodak A, Ali R, Lintzeris N.

Application to the NHMRC (not funded)

\$151,632 (year 1)

\$149,132 (year 2)

Pilot randomised controlled trial of dexamphetamine prescribing as substitution therapy for cocaine dependence.

Wodak A, Mattick R, Shearer J, van Beek I.

(funded January 2000)

\$68,044

Follow up study of subjects in a randomised controlled trial of methadone treatment in prison.

Dolan K, Wodak A, Kaldor J, Hall W.

(funded January 2000)

\$60,632

A cost-effectiveness analysis of prison methadone programs in Australia.

Dolan K, Wodak A, Shiell A.

(funded January 2000)

\$61,157

A randomised controlled trial comparing naltrexone maintenance, methadone maintenance and drug free counselling for injecting drug use inmates.

Dolan K, Wodak A, MacDonald M.

\$171,253 (year 1),

\$102,998 (year 2),

\$34,889 (year 3)

## 19. EDITORIAL BOARDS:

- (1) Assistant Editor, Member of International Editorial Board, Addiction
- (2) Current Therapeutics
- (3) Medicine Today
- (4) International Journal of Drug Policy.
- (5) Drug and Alcohol Review
- (6) Member of International Advisory Board, Addiction Abstracts

## 20. REFEREE MANUSCRIPTS:

- (1) Medical Journal of Australia
- (2) Australian and New Zealand Journal of Medicine

- (3) Australian and New Zealand Journal of Public Health
- (4) Addiction
- (5) Modern Medicine
- (6) Drug and Alcohol Review
- (7) Australian and New Zealand Journal of Psychiatry

### **Statement of research achievement.**

I began to advocate for a national institute of alcohol and drug studies in 1984. These efforts ultimately led to a national commitment to establish such a centre. Two colleagues and I succeeded in attracting the centre to UNSW in competition with a number of other universities. I then served on a small planning committee for what became known as the National Drug and Alcohol Research Centre (NDARC). NDARC was opened in 1987.

I proposed the development of a standardised instrument to measure the outcome of drug treatment to the then Director of NDARC. The proposal was accepted and this led to the development of a now widely used instrument (called the 'Opiate Treatment Index').

A paper I wrote with colleagues on HIV testing among drug users in treatment in Sydney in 1985 was the first scientific research on this subject published in Australia.

In 1985, I was provided funding to undertake a drug education project. The project which developed was based on the notion that the target population (young drug users) were to be actively involved in the design and implementation of all products, that drug use was considered to be something to be managed rather than eradicated and that the means of communication would involve popular music and video. This project produced the first harm reduction drug education in the country.

In November 1986, my colleagues and I established the first needle syringe programme in Australia. Although pre-legal at the time, the NSW Government soon accepted the need to establish legal needle syringe programmes and all other jurisdictions in the country soon followed suit. In 2002, independent research estimated that the needle syringe programme in Australia had by 2000 prevented 25,000 HIV infections and 21,000 hepatitis C infections, saved \$2.4-7.5 billion and by 2010 will have prevented 4,500 AIDS deaths and 90 hepatitis C deaths.

My colleagues and I published papers on the serological testing of fluid contained in used needles and syringes handed in to needle syringe exchange programmes. This introduced a novel technique subsequently used by researchers in many other countries.

I devised a study in 1987 to determine whether the needle syringe programme established in 1986 had a detrimental effect on a nearby methadone maintenance centre by comparing the results of urine analysis of the methadone patients with a distant methadone unit. This study found no evidence of any detrimental effect and was one of six studies cited by the General Accounting Office (the research arm of US Congress) to reach the conclusion that needle syringe programmes do not exacerbate illicit drug use.

In 1989, I was a principal investigator of the Australian National AIDS and Injecting Drug Users Study (ANAIIDUS). This was the first major national cross sectional study of injecting drug users in the country. I was also a principal investigator of the subsequent Australian Study of HIV infection and Injecting Drug Use (1994/95) which developed this research approach further. I was also a member of an international collaborative group conducting similar research in a number of countries, co-ordinated by the World Health Organisation.

In 1989 I established the first government-funded organisation of injecting drug users in Australia. Now there are similar organisations in all states and territories and a national organisation.

Anticipating the need for more regular surveillance of drug use, demographic characteristics, risk behaviour and serology of blood borne viruses, I proposed an annual survey of persons attending needle syringe programmes to the National Centre for HIV Epidemiology and Clinical Research. This project was subsequently taken up. This survey has become a very valuable (and inexpensive) source of data about drug use, HIV and HCV in Australia.

I have been involved in a major evaluation of methadone treatment in prisons. This is the first time in the world that a randomised control trial has been conducted of methadone treatment in a corrections environment. This study has been completed and a four-year follow up study has been completed.

I started a project evaluating dexamphetamine prescription for amphetamine dependence. The first study in this series was a pilot project to assess the feasibility of conducting a randomised control trial of this intervention. This was the first randomised control trial in the world of dexamphetamine prescription for amphetamine dependence.

My colleagues and I have commenced a randomised control study comparing methadone, naltrexone and usual care among prison inmates. This is the first study of this kind in the world.

The US National Institute of Drug Abuse and the World Health Organisation invited me to join the Global Research Network in 1998. I currently co-chair the committee overseeing this project. I have been invited on several occasions to deliver papers comparing HIV prevention policies for injecting drug users and outcomes in the USA and Australia including by the US National Academy of Sciences and more recently by the James A Baker III Institute, Rice University, in Houston, Texas.

In May 1999, my colleagues and I established the first medically supervised injecting centre in Australia. This was pre-legal at the time. On July 27, 1999 the NSW Government invited the Sisters of Charity Health Service to establish an officially sanctioned medically supervised injecting centre.

Revised: Tuesday, 21 February 2006